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          Opioids are prescribed to millions of people each year, especially to help patients cope 
with chronic pain, something from which more than a fifth of U.S. adults suffer (CDC). 
Unfortunately, opioid use and abuse has become a national emergency as the number of opioid 
prescriptions, opioid misuse, and opioid-related drug overdoses and death have drastically 
increased in the last twenty years (HHS). Because of the emergent state surrounding opioid use 
and misuse, the effects of opioids on all aspects of the human body has been an increasingly 
large focus of research scientists. This study focuses on the possible effect of repeated opioid 
administration on the gut microbiome.  
        The human gut microbiome has also been a significant focus for researchers recently as 
more evidence is unveiling the effects of the gut microbiome on several organs of the body, 
especially the brain (Galland). It remains unclear the mechanism by which opioids affect humans 
beyond pain management, particularly cognitive function, mood and behavior. Given the 
similarities of side effects between gut microbial dysbiosis and chronic opioid use, including 
decreased gut motility, increased inflammation, altered cognitive function, and behavioral 
changes, it is possible that some of the effects of opioids on the brain’s cognitive functions are 
mediated through microbial effectors due to alterations in gut microbial composition upon 
prolonged usage of opioids. Therefore, our lab took special interest in the possible link between 
opioids, the gut, and the brain.  
            It was our aim to provide evidence that repeated Buprenorphine, a partial µ-opioid 
receptor agonist, dosing alters gut microbial composition. By first isolating DNA from non-
human primate fecal samples and analyzing DNA quality we were able to prepare DNA libraries 
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and perform DNA Illumina Next-Generation shotgun sequencing. At the phylum level we 
observed a fairly common trend in treated subjects of increased Firmicutes during dosing 
followed by a decrease toward baseline after one week post-dosing. We also observed increases 
and decreases in the sub-dominant phylum in treated subjects at two weeks of dosing followed 
by a respective decrease or increase toward baseline after one week post-dosing; however, these 
trends were less consistent. At the genus level we were unable to observe any trends as a result 
of opioid administration. Upon performing a non-parametric Wilcoxin Signed-Rank Test, it was 
determined that there was no significant differential abundance between time points in treated 
subjects. Quantitative PCR was also performed to validate our sequencing results, but 
considering the lack of trends we observed, it proved to be difficult to validate anything. 
 In the end, we were unable to provide significant evidence for our hypothesis. The gut 
microbiome varies so greatly among and within individuals that finding a significant and 
consistent alteration in bacterial abundance across all treated subjects proved nearly impossible. 
What we were able to take away from the study was the observation of some alteration in the 
microbiome which will need to be studied further by incorporating predicted experimental 
improvements gleaned from our pilot studies. Despite our results, it is still our hypothesis that 
opioids affect the microbiome and we encourage future researchers to use our findings as a guide 




Chapter 1 – Background  
 
1.1 - Gut Physiology Overview  
 
Figure 1. Schematic of gastrointestinal activity including motility, secretion, digestion, and absorption. Purple indicates ingested 
material.  
 
        The gastrointestinal tract encompasses a pathway consisting of multiple organs that 
allow for the digestion of ingested material. Beginning at the oral cavity where material is 
first ingested, mechanical digestion (chewing) occurs. This allows for the formation and 
passage of a bolus to the esophagus which utilizes peristalsis to move said bolus to the 
stomach. In the stomach, acids and other enzymes transform the bolus to chyme until it is 
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liquid enough to be passed to the small intestine. The small intestine is where most secretions 
are added and absorption occurs allowing for the removal of nutrients that can be supplied to 
the body. From the small intestine, the remainder enters the large intestine where some 
secretions are added such as water and mucus followed by absorption of vitamins, 
electrolytes, and water, resulting in the production of feces. Generally, absorbed materials 
flow through the hepatic portal system to enter the liver first so that nutrients can be removed 
and stored, and toxic materials can be filtered out. While this process is successful in a 
healthy gut, an “unhealthy gut” can have detours caused by gut permeability. Gut 
permeability is caused by a decrease in the protective bacterial barrier that generally exists 
along the gut walls. This permeability allows partially digested food, toxins, and 
microorganisms to escape to the bloodstream or impact the underlying gut tissue rather than 
follow the process detailed above.  
         The walls of the gastrointestinal tract are comprised of many different tissues. The 
epithelial cells lie on the mucosa, the innermost part of the gut wall, closest to the lumen. 
There are different types of muscle that make up the gut wall that assist in gut motility and 
digestion. In addition, the myenteric and submucosal plexuses make up the enteric nervous 
system, which is specific to the gut. The general makeup of the gut wall can be seen in Figure 
2. However, each region of the gut has unique characteristics of the gut wall that enable it to 
function differently from its counterparts; therefore, Figure 2 does not accurately represent 
all regions of the gut. For instance, regions of the small intestine include glands that allow for 
secretions, Peyer’s patches for protection from pathogens, and villi and crypts for absorption; 




Figure 2. Layers of the gut wall  
1.2 - The Gut Microbiome  
         The gut microbiome is comprised of the Bacteria, Archaea, and Eukarya that live in the gut 
(Thursby).  The microbiome is formed at birth, as the baby travels through the vaginal canal or, 
in cases of caesarian section, is exposed to other humans and surrounding air. There are two 
phyla that typically dominate the human gut, Firmicutes and Bacteroidetes. Under Firmicutes 
falls Clostridium, Enterococcus, Lactobacillus, and Ruminococcus while Bacteroides and 
Prevotella fall under Bacteroidetes. After birth, Enterobacteriaceae, Streptococci, and 
Staphylococci dominate the microbiome and as time proceeds the three genera that dominate 
become Bacteroides, Prevotella, and Ruminococcus (Power).   
1.2a – Diversity in the Microbiota 
         Proceeding from the stomach to the large intestine, the amount of diversity in the 
microbiota increases significantly. Based on metagenomic sequencing of fecal matter from 124 
individuals, it was found that there are between 1,000-1,500 bacterial species present in the gut 
microbiome, 160 of such species belonging to each individual (Qin). Building on what was 
13 
 
previously stated, the most common genera of bacteria found in humans are Bacteroides, 
Bifidobacterium, Eubacterium, Clostridium, Peptococcus, Peptostreptococcus, and 
Ruminococcus. However, every person has a different variety of species related to these genera 
within them and generally have a unique combination of these species that dominate (Gaurner).  
        The different bacteria in the gut can be characterized by their function and the conditions in 
which they can function. Facultative anaerobes and aerobes are organisms that can function 
aerobically in the presence of oxygen or anaerobically in the absence of oxygen, but prefer the 
conditions indicated by their name. Obligate (strict) aerobes require oxygen to function while 
obligate (strict) anaerobes cannot survive in conditions in which oxygen is present. The colonic 
region of the gastrointestinal tract contains higher levels of obligate anaerobes and lower levels 
of facultative aerobes compared to other regions (Rastall). Of the dominant bacteria in the gut, 
Bacteroides, Eubacterium, Bifidobacterium, and Peptostreptococcus are all examples of strict 
anaerobes (Holzapfel). Among the subdominant genera are facultative anaerobes such as 
Escherichia, Enterobacteria, Enterococcus, Klebsiella, Lactobacillus, Proteus, and 
Streptococcus (Gaurner).  
         Pathogenic bacteria include those that have the ability to cause disease. Examples of 
pathogenic bacteria that can be found in the gut are those of the genus Clostridia as well as 
species such as Eschericia coli. More specifically, it is known that Clostridium difficile can cause 
inflammation of the colon and E. coli causes diarrhea. The gut microbiome is generally balanced 
so that pathogenic bacteria remain at low levels, however disruption of the balance can lead to 
both infection caused by exogenous pathogens and increased growth of endogenous pathogens 
which can lead to increased susceptibility to disease (Gorbach).  
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         Probiotics are beneficial bacteria whose ingestion should enhance colonization of such 
bacteria resulting in strengthened defense against pathogens along the gastrointestinal tract. 
Lactobacilli are considered beneficial bacteria that are often used as probiotics to strengthen 
pathogen defense (Rastall). In addition, Bacteroides fragilis is another known probiotic 
(Galland).  
         Figure 3 depicts common bacteria found in the gut as either potentially pathogenic or 
beneficial (Kamada, Rastall, Rolhion).   
Pathogenic Beneficial 
Clostridia (OAn*) Lactobacillus (FAn) 
Escherichia coli  (FAn) Bifidobacterium  (OAn) 
Citrobacter (FAn) Bacteroides (OAn) 
Salmonella (FAn) Proteobacteria 
Proteobacteria Eubacterium (OAn) 
Figure 3. Health negative (pathogenic) and health positive (beneficial) bacteria in the human gut. OAn indicates Obligate anaerobe, Fan 
indicates Facultative anaerobe. OAn* indicates a bacterial genus that sometimes acts as an obligate anaerobe but not always. Proteobacteria 
appears in both columns as genera from this phylum can be either potentially pathogenic or beneficial.   
1.2b - Function of the Gut Flora  
           The gut flora has been linked to many regulatory processes in the body. Some important 
roles of the gut bacteria include that of metabolic processes, immune responses, cell 
development, hormone regulation, and mental health (Gaurner, Galland, Clarke).  In addition, the 
gut flora are partially responsible for the degradation of certain food components and production 
of some vitamins and digestive or protective enzymes (Holzapfel). The gut microbiota also plays 
a role in the transformation of primary bile acids and thus may have involvement in lipid and 
glucose metabolism (Clarke). Largely, the gut flora can be described as a protective barrier 
between the gut lumen and the rest of the body. The intestinal epithelium is the path through 
which absorption of nutrients occurs, therefore the flora residing in the intestinal epithelium acts 
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as a barrier against uptake of pathogenic microorganisms, antigens and anything else that could 
be harmful to the body from the gut lumen (Holzapfel). Ideally, harmful substances would be 
successfully blocked from absorption by these intestinal bacteria and then degraded or excreted 
from the body.  
1.2c - Microbial Dysbiosis 
           Microbial eubiosis refers to the state of the gut in which the bacterial environment is 
balanced. In this state, beneficial bacteria are able to compensate for harmful bacteria so that the 
gut remains healthy. More specifically, the dominating, beneficial bacteria generally belong to 
the phylum Firmicutes and Bacteroides, while the harmful bacteria, of phylum Proteobacteria or 
Enterobacteriaceae, is present in a much lower concentration. In microbial dysbiosis, the 
bacterial environment becomes unbalanced as the beneficial bacteria are overcome by the 
harmful bacteria (Iebba). 
         Microbiota can affect intestinal function in several ways including motility, digestion, 
permeability, and secretion. In addition, components of the microbiota have the ability to leave 
the gut and enter circulation which allows for dispersal to other organs of the body like the brain, 
liver, and pancreas affecting their function (Iebba). Therefore, microbial dysbiosis poses a 
potential threat to intestinal function as well as other organs of the body.  
1.2d - The Gut Microbiome and the Brain   
         There are several ways in which the gut microbiome can affect the brain. First, there is a 
direct link between the gut bacteria, the enteric nervous system, and the brain via the vagus 
nerve. This connection is given the name the gut-brain axis and can be seen in Figure 4 (Galland, 
Clarke). Signaling molecules, secreted or controlled by gut microbiota, talk to vagal afferent 
nerves, both motor and sensory, which transmit signals to the brain. This innervation can affect 




Figure 4. The relationship between the gut’s enteric nervous system and the central nervous system   
          In addition, there is an indirect relationship between the gut and brain via the immune 
system. Gut bacteria can trigger stimulation of the innate immune system through gut 
permeability or dysbiosis which acts further to cause systemic or central nervous system 
inflammation (Galland). In a dysbiotic state, the gut wall’s protective barrier becomes 




             In further detail, a component of the bacterial cell wall, lipopolysaccharides (LPS), 
induces synthesis of cytokines by the innate immune system. Therefore, increased bacteria leads 
to increased LPS which causes increased synthesis of pro-inflammatory cytokine, IL-6 and 
TNFα, anti-inflammatory cytokines, IL-10 and IL-1 receptor antagonist, as well as cortisol and 
epinephrine resulting in depressed mood, increased anxiety, impaired long-term memory, and 
interrupted sleep (Galland). In a study of chronic alcoholics, Leclercq et al. used Cr51-EDTA to 
determine intestinal permeability and split individuals into two groups based on high or low 
permeability. As stated previously, intestinal permeability is a factor that contributes to immune 
response and thus inflammatory response. Those with high permeability showed greater signs of 
depression, anxiety, and alcohol dependency than those with low permeability. In addition, those 
with high permeability had decreased colonization of Bifidobacterium, a known anti-
inflammatory bacteria (Leclercq). This study provides evidence that bacterial dysbiosis can cause 
decreased protection of the gut wall leading to gut permeability and an immune response that 
leads to CNS inflammation and ultimately altered CNS function. The adaptive immune system 
also plays a role in that antigens may react with these bacteria to cause an immune response. 
          Lastly, these bacteria produce potentially neurotoxic metabolites like D-lactic acid, 
ammonia, and short-chain fatty acids. Again, increased permeability of the gut wall leads to 
increased production of these neurotoxic metabolites which have been linked to disorders such as 
Autism Spectrum Disorder (Galland).   
        Gut Microbial dysbiosis has been linked to several mental disorders. The aforementioned 
relationships provide a connection between the gut and the brain which allow the gut 
microbiome to impact memory, mood, and cognition (Galland). Wikoff et al. performed a study 
in germ-free mice to look at this gut-brain relationship. They found that in GF mice, synthesis of 
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most of the chemicals in the blood relies on the gut microbiome and these chemicals influence 
behavior and/or neuroendocrine response. Additionally, they determined that the microbiome 
affects brain development as they saw that in GF mice, developmental abnormalities were 
reversible by intestinal bacterial colonization only in early life (Wikoff). 
         The gut can also be viewed as an endocrine organ because of its ability to produce and 
control compounds that enter circulation which travel to and affect distant organs (Clarke). 
Neuroendocrine mechanisms affect the CNS in a variety of ways depending on the 
neurotransmitter or hormone that is produced by the gut. Large amounts of GABA (γ-amino 
butyrate), the most important inhibitory neurotransmitter in the brain, are produced by intestinal 
bacteria, like Lactobacillus and Bifidobacterium (Clarke, Galland). GABA regulates the 
hypothalamic-pituitary-adrenal (HPA) axis, which is activated in response to stress. The HPA 
system is set up so that stress induces the release of corticotrophin releasing hormone (CRH) 
from the hypothalamus which stimulates the synthesis and release of adrenocorticotropic 
hormone (ACTH) from the anterior pituitary which stimulates the synthesis and release of 
glucocorticoids from the adrenal cortex. The goal of HPA axis stimulation is production of 
glucocorticoids like cortisol which functions to regulate cardiovascular, metabolic and 
immunologic changes during stress events (Crowley). GABA inhibits CRH release meaning 
altered GABA release can alter glucocorticoid production during stress events (Barden). It is 
theorized that dysregulation in GABAergic transmission is linked to stress-related psychiatric 
disorders (Crowley). Evidence already exists that patients suffering from severe depression have 
HPA system alterations (Barden).  
         Escherichia are known to induce production of norepinephrine, serotonin and dopamine, 
examples of monoamine neurotransmitters. These neurotransmitters are involved in a variety of 
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processes including cognitive function, mood alteration, sympathetic nervous system action, 
regulation of movement, and more (Kema, Ressler, Tzchentke). Streptococcus and Enterococcus 
also produce serotonin and Bacillus produces norepinephrine and dopamine. Lactobacillus 
produces acetylcholine, the neurotransmitter used at the neuromuscular junction (Galland). 
Bacterial fermentation of carbohydrates and proteins in the gut lead to the production of short 
chain fatty acids (SCFAs), like butyrate or propionate. Many bacteria are known to produce 
SCFAs including Bacteroides, Bifidobacterium, Propionibacterium, Eubacteria, Lactobacillus, 
Clostridium, Roseburia, and Prevotella. SCFAs have several functions including modulation of 
enteroendocrine serotonin (5-HT) secretion and peptide YY (PYY) release and they affect 
several mechanisms in the body including epithelial cell transport, metabolism, growth and 
differentiation, hepatic control of lipids and carbohydrates and are a source of energy for 
muscles, kidneys, the heart and the brain (Clarke). Figure 5 summarizes some of the bacteria that 
produce or release important neurotransmitters.  
Neurotransmitter Bacteria  




Dopamine Bacillus subtilis 
Escherichia coli 
Noradrenaline Bacillus subtilis 
Escherichia coli 
GABA Lactobacillus brevis 
Bifidobacterium  
Figure 5. Bacterial strains that produce common neurotransmitter 
1.2e - Diet on the gut microbiome  
          Bacteroides dominant microbiomes are associated with high protein and animal fat diets, 
while Prevotella dominant microbiomes are associated with high carbohydrate diets. 
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Additionally, there is an increase in Firmicutes and decrease in Bacteroidetes correlated with the 
high-fat and high-sugar Western diet (Clarke).  
           Diet includes not only food consumption but also consumption of any foreign substance, 
including drugs. Just as probiotics are ingested to alter the gut microbiota to increase abundance 
of beneficial bacteria, other drug consumption, like that of antibiotics, anti-inflammatories, or 
analgesics may alter the microbiota either positively or negatively.  It is expected that individuals 
following the same diet could maintain more similar gut microbial composition. However, age, 
gender, and other factors must also be considered.  
1.3 - Opioids and Pain Management 
            According to the CDC’s analysis of the 2016 National Health Interview Survey (NHIS) 
date, nearly 20% of U.S. adults, or 50 million people, suffer from chronic pain (CDC MMWR). 
Opioids are one of the most effective drugs for pain management, both acute and chronic 
(Rosenblum). However, it is estimated that 11.4 million people misused prescription opioids in 
2017 and unfortunately, almost 80% of heroin users claim that they misused prescription opioids 
prior to using heroin (HHS Opioids). In 2017 the HHS declared a public health emergency as a 
result of the opioid epidemic and thus research on this topic is pertinent to understanding opioid 
effects on the human body as well as finding alternative pain treatment to reduce the opioid 
misuse/overdose statistics.  
1.3a - Pharmacology of Opioids and Opioid Metabolism 
          It is important to note that opioids can be produced endogenously or taken in the form of a 
drug, the latter being the focus of this project. Opioid metabolism refers to the process by which 
the body breaks down the drug so that it can be eliminated from the body. Ingested opioid drugs 
must travel through the gastrointestinal tract before entering the liver’s portal system. Once in 
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the liver, the first phase of metabolism occurs after which the opioids may enter systemic 
circulation to travel to target tissues (Smith).   
         The purpose of opioids is to inhibit pain sensation. To do this, opioids activate opioid 
receptors, which are among the g protein-coupled receptor family (GPCRs), on nerve cells, 
mostly found in the brain (NIH How opioid drugs activate receptors). While these receptors are 
largely found in the central nervous system, they are also found in the peripheral nervous system, 
as well as the gastrointestinal tract and the myenteric plexus of the enteric nervous system 
(Farzi). When opioids activate opioid receptors, like the µ-opioid receptor, they inhibit the 
signals produced by neurons as a result of painful stimuli from reaching the brain, in addition to 
increasing the release of dopamine, resulting in decreased pain and a euphoric state (ATrain 
Education).  
          There are three known opioid receptors, μ, δ, and κ which belong to the rhodopsin family 
of g protein-coupled receptors. They couple with Gi/Go proteins which cause a cascade of 
intracellular events including inhibition of adenylyl cyclase activity, inhibition of voltage-gated 
Ca2+ channel opening and thus decreased neurotransmitter release from presynaptic terminals, 
stimulation of K+ channels such as GIRKs causing hyperpolarization and inhibition of 
postsynaptic neurons, and activation of PKC and PLCβ. Opioids are most effective in reducing 
pain for acute nociception and tissue injury and can work supraspinally, at the level of the spine, 
and peripherally. Supraspinally, μ-opioid receptor agonists inhibit the release of GABA from 
periaqueductal gray (PAG) matter. At the level of the spine, opioids decrease the release of 
spinal neurons typically discharged as a result of pain stimuli to reduce sensitivity to somatic and 
visceral stimuli that evoke pain as well as reducing release of neurotransmitters. Peripherally, 
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opioid application produces local anesthetic-like action and reduces over-sensitization in regions 
suffering from inflammation (McGraw Hill).   
1.3b - Buprenorphine  
          This study will focus on Buprenorphine, a partial µ-opioid receptor agonist, which has 
been compared to other commonly prescribed opioids such as morphine and methadone. In one 
study it was shown that buprenorphine lasts longer than morphine, requiring fewer doses for the 
same analgesic effects, and has similar side effects (Tigerstedt). In a different study, 
buprenorphine was compared to methadone and results showed similar efficacy in the treatment 
of opioid dependence for both drugs (Strain). Buprenorphine is generally prescribed for one or 
more of three reasons: opioid detoxification, opioid maintenance, and pain management. It is 
considered a semi-synthetic opioid derived from the alkaloid, thebaine, from the opium poppy, 
Papaver somniferum. As a partial µ-agonist, this drug has no effect after a certain dosage when 
receptor activation plateaus. It also has a high affinity for the µ-opioid receptor and dissociates 
slowly, allowing it to act for a longer period than other opioid drugs (Welsh).  
1.3c - Common Side Effects of Opioids  
          Some of the most common side effects of opioid usage are constipation, nausea, vomiting, 
confusion, depression, and susceptibility to disease (CDC Opioid Overdose)., Opioids decrease 
intestinal motility by inhibiting myenteric activity. The decreased motility increases the 
likelihood of bacterial translocation as substances are forced to remain in certain regions of the 
GI tract longer than normal (Balzan). This promotes a link between opioids and susceptibility to 
disease. In addition, decreased intestinal motility encourages constipation because fecal matter 
sits in the large intestine longer, allowing more absorption to occur than usual, causing 
compressed and hardened feces. It is understood that a change in the composition of the gut 
microbiota is associated with chronic constipation. Generally, this would include a decrease in 
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obligate bacteria, Lactobacillus, Bifiodbacterium, and Bacteroides and an increase of pathogenic 
microorganisms like Psuedomonas aeruginosa and Campylobacter jejuni (Zhao). 
          The effects of opioids on mental health have been a more recent focus of research. In 
2016, a long-term study determined that opioid use lasting greater than 30 days increases the risk 
of new-onset depression. The study was comprised of over 100,000 patients age 18-80 over a 12-
year time frame. Each patient was a new opioid user and did not present with depression at the 
time of opioid treatment. Results concluded that between 9-12% of patients reported new-onset 
depression after opioid use. In addition, this percentage was increased in cohorts of patients 
using for greater than 30 days: 10.7% of patients using 1-30 days reported depression compared 
to 14.8% of patients using 31-90 days and 19% of patients using longer than 90 days (Scherrer). 
This study provides support for the link between opioids and mental health, furthering the appeal 
to study the mechanisms responsible for such results.  
1.4 – The Link Between the Gut Microbiome and Opioid Use 
   
          There are limited studies relating the gut microbiome and opioid use, but there are a 
handful that provide evidence for a possible link between opioid use and the gut microbiome. In 
a study by Acharya et al. chronic opioid use was related to altered gut microbiota in patients with 
cirrhosis. This study was composed of two cohorts, one with 200 cirrhotic patients both with and 
without opioid use and the other with 72 cirrhotic chronic opioid users and 72 cirrhotic non-
opioid-users. Using stool, they determined the composition of the microbiota of these patients 
and discovered that opioid users in cohort 2 had significant microbial dysbiosis, specifically a 
decrease in autochthonous taxa and Bacteroidaceae abundance. In cohort 1, they saw an increase 
in “all cause” readmission in cirrhotic opioid users, indicating a possible link to opioid use, 
microbial dysbiosis, and pathogen susceptibility. In a study by Banerjee et al. it was shown that 
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opioid-induced gut microbial disruption leads to gut barrier compromise and systemic 
inflammation in C57B16/j mice. Using bacterial 16srDNA sequencing they found that chronic 
morphine treatment significantly altered the gut microbial composition. They saw an increase in 
gram-positive Firmicutes phyla, specifically families Enterococcaceae, Staphylococcacaea, 
Bacillaceae, Streptococcaceae, and Erysipelotrichaeceae, and a decrease in phyla Bacteroidetes 
as a result of opioid dosing. Because of a lack of research on this topic, especially in animals 
closely related to humans, a pilot study is necessary for providing evidence for the link between 
the gut microbiome and opioid use. Researchers are limited in their ability to gather willing 
participants for such a study. Even if willing human participants are available, like in the 
Archarya study, the presence of other health conditions creates compounding factors that may 
influence results. Therefore, healthy animal models are most likely the most available and 
reliable participants of such a study.   
         Phylogenetically, humans, non-human primates, and rodents all stem from a common 
mammalian ancestor. Rodents, rather than non-human primates, are often chosen as the subjects 
in scientific studies that aim to provide insight into human microbiology, biochemistry, 
physiology, etc. However, because the gut microbiome varies so greatly, even among humans, to 
provide the most significant results, it was pertinent to choose subjects most closely related to 
humans, that being non-human primates i.e. rhesus monkeys. In 2007, the genome of the rhesus 
macaque monkey was discovered, and it was determined that rhesus monkeys and humans share 
about 93% of the same DNA (Gibbs). Chen et al. performed a study looking at the diversity in 
the rhesus macaque microbiota compared to that of humans and found that similarly to humans 
the microbiota is rich in Bacteroidetes, Firmicutes, and Proteobacteria, but phylotypes varied at 
different body sites. Importantly, the anal community, indicative of the gut microbiome had an 
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increased abundance of Prevotella which differs from humans whose gut microbiome is 
dominated by Bacteroides. Despite the differences, they concluded that rhesus monkeys are a 
good animal model for characterization of microbes. Yet, it is important to understand that 
despite the genomic and microbial similarity between humans and rhesus monkeys, it remains 
possible that the baseline gut microbial composition of these animals is different than what we 






Chapter 2 - Hypothesis and Aims 
2.1 - Hypothesis 
      We hypothesize that repeated opioid dosing alters the gut microbiome such that beneficial 
bacterial abundance decreases while potentially pathogenic bacterial abundance increases. We 
expect that this alteration influences other organs in the body, most importantly the brain, and 
plays a role in the mechanism by which opioids alter the psychological state of individuals.  
2.2 - Aims 
Aim 1. To characterize the baseline gut microbial composition of the subjects and 
determine the extent of variation in the baseline composition among the different 
subjects. 
Aim 2. To determine if opioid dosing affects the gut microbiome using shotgun 
sequencing and qPCR methods. If there is a change, we aim to characterize said change 
in terms of beneficial/pathogenic bacterial abundance. 
Sub-Aim 2-1. To compare the gut microbial composition before dosing to that at 
one week of dosing. 
Sub-Aim 2-2. To compare the gut microbial composition before dosing to that at 
two weeks of dosing. 
Aim 3. If there is a change in the gut microbiome from pre-dosing to during-dosing, we 





Chapter 3 – Materials and Methods 
 
3.1 - Overview 
 
Figure 6. Materials and methods workflow 
3.2 - Subjects  
         Nine rhesus monkeys were selected to participate as subjects in this study, four females and 
five males. The four females are subjects 1533, 1542, 1543, and 1544 and the five males are 
subjects 1496, 1497, 1500, 1501, and 1532. Of these nine, four were in the control group and 
five were in the Buprenorphine treatment group as shown in Figure 7. 
Control Group  Buprenorphine Treatment Group 
1496 (M) 1497 (M) 
1501 (M) 1500 (M) 
1533 (F) 1532 (M) 
1542 (F) 1543 (F) 
 1544 (F)  
 
Figure 7. Control group subjects versus treatment group subjects. M represents males and F represents females.  
3.3 - Drug of choice 
         Buprenorphine was chosen as the opioid used in this study. Buprenorphine, a partial 
agonist, has a lower efficacy as it is less effective at stimulating the µ-opioid receptor compared 
DNA Isolation from fecal samples
Gel Electrophoresis
qPCR 
DNA Library Preparation and Purification 
DNA Sequencing and Analysis
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to full agonist opioids used for pain management like Oxycodone or Morphine. The half-life of 
Buprenorphine is also longer than that of stronger analgesics. While Buprenorphine is a less 
intense opioid drug, it is still known to cause similar gastrointestinal problems as other opioids, 
such as inflammation, constipation, and nausea.  
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1532 X       X    X  X   X  X   
1533* X     X    X  X   X  X   
                     
Cohort 
2                     
Subject                     
1542* X    X    X  X   X X    
1543 X    X    X  X   X  X   
1544 X       X    X  X   X  X   
                                  
Cohort 
3                 
Subject         
1 








1496* X X         
Start 
dosing  X   X    X X 
1497   X X       X   X    X X 
1500   X  X      X   X    X X 
1501* X X            X   X    X X 
 
Figure 8. Treatment and sample collection schedule. * indicates control subjects. X indicate sample collection.  
      Dosing occurred over a seventeen-day period and Buprenorphine/Saline was administered 
via intramuscular injections. Subjects 1532 and 1500 were administered 0.1mg/kg daily in 
divided doses while the remaining subjects were administered 0.03mg/kg daily in divided doses. 
Control subjects were administered saline in place of Buprenorphine. During dosing, lab 
assistants constantly checked for precipitate withdrawal.  
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      Stool was collected from each subject at different time points before dosing, during dosing, 
and after dosing. Stool samples were stored in a -80° freezer and thawed when necessary for 
DNA isolation.  
3.5 - DNA Isolation  
      Stool samples were thawed and a 200mg (+/- 50mg) portion was aliquoted into a clean 
microcentrifuge tube to be used for isolation as directed by the PureLink Microbiome DNA 
Purification Kit User Guide for Stool Samples (Invitrogen), the protocol chosen for DNA 
isolation. The concentration (ng/µL) of isolated DNA was found via the Nanodrop 
Spectrophotometer and the purity of the sample was observed using the “Purity A260/A280” 
ratio given by the machine, which quantifies the absorbance maxima of nucleic acids, at 260 nm 
and 280 nm. A A260/A280 ratio nearing 2.0 is the aim for such samples to indicate minimal 
impurities. The A260/A230 ratio is also used to assess solvent contamination in the DNA 
samples and this ratio should be greater than 1.8.  
3.6 - Gel Electrophoresis  
        Following DNA isolation, gel electrophoresis was performed on the DNA samples to 
observe possible degradation. The apparatus was prepared with a .8% agarose gel made from 
TAE buffer, agarose, and red dye. Upon hardening of the gel, it was submerged in TAE buffer. 
5µL of DNA sample was combined with 1µL loading dye and inserted into the gel wells and ran 
at 75V for 45 minutes.   
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3.7 - Quantitative PCR (qPCR) 
 
Figure 9. Depiction of SYBR Green based qPCR  
For each 96-well qPCR plate that was run, each well was filled accordingly with 10µL 
SYBR Green Master Mix, 9µL nuclease free water, 0.1µL forward primer, 0.1µL reverse primer, 
and 1µL 10ng/µL diluted DNA sample. Plates were run in triplicate, meaning each DNA sample 
was added to three wells containing the same primer. Additionally, each primer was added to a 
control well in which no DNA sample was added so that primers could be assessed for 
contamination. Each qPCR plate was run on the QuantStudio Real-Time PCR machine which 
provided average threshold cycle values for each DNA sample with each primer which were 
used to quantify bacterial levels in the DNA samples. The thermocycler was set to forty cycles, 
therefore CT values only go as high as forty.  
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 3.7a - qPCR Primers 
We originally selected nine primers designed by other researchers. The two 
Domain Bacteria primers were used as universal primers to determine the abundance of 
bacteria as a whole in the DNA sample. The remainder of the primers were chosen 
because they are known as typically abundant bacteria in humans. Clostridium and 
Spirochaete were chosen because their abundance often increases in inflammatory states. 
After numerous attempts it was found that the Bifidobacteria primer was ineffective and 
due to extraneous circumstances, we were unable to replace the primer. Therefore, in the 
end we utilized eight primers to verify sequencing results provided by Hermann-Bank et 
al.  
Target Primer sequences (5’→ 3’) Positions 
(bp) 
Spirochaetes  Forward GTYTTAAAGCATGCAAGTC 294 
Reverse TGCTGCCTCCCGTAGGAG 
Domain Bacteria A 
V2-V3 
Forward AGAGTTTGATCCTGGCTCAG 336 
Reverse CTGCTGCCTYCCGTA 
Domain Bacteria B 
V4-V5 
Forward CAGCAGCCGCGGTAATAC 389 
Reverse CCGTCAATTCCTTTGAGTTT 




Forward TGAAAGATGGCATCATCATTCAAC 258 
Reverse GGTACCGTCATTATCTTCCCCAAA 




Forward GTTAATACCTTTGCTCATTGA 320 
Reverse ACCAGGGTATCTAATCCTGTT 
Phylum Fusobacteria Forward GATCCAGCAATTCTGTGTGC 292 
Reverse CGAATTTCACCTCTACACTTGT 
 
Figure 10. qPCR primers 
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3.8 DNA Library Preparation 
 
 
Figure 11. DNA library preparation, purification, and sequencing workflow   
DNA libraries were created using the Takara Bio ThruPLEX DNA-seq Kit and User 
Manual. Samples were diluted so that 1 µg DNA went into 52.5 µL H2O making each sample 
equal to 20 ng/µL. Following dilution, each sample was transferred into a covaris tube and then 
fragmented using the Covaris S2 Sonication machine. To do so, the sonication machine’s tank 
was filled with dH2O, degas was turned on, water was cooled to 4-6°C and each sample was 
fragmented for 50s. Subsequently, 1 µL fragmented DNA was mixed with 9 µL H2O into PCR 
tubes rather than 10 µL fragmented DNA as suggested by the ThruPLEX DNA-seq Kit User 
Manual. This was done so that in the Library Amplification step, the amount of input DNA was 
20 ng/µL, therefore the thermocycler was set for six PCR cycles. In addition, we used a dual 
index 96-well plate.  
Pre-Libary 
Preparation
•Fragment DNA using Sonicator




















Figure 12. Overview of DNA library preparation with Takara Bio ThruPLEX DNA-seq kit  
3.9 - DNA Library Purification  
AMPure beads were used to purify DNA libraries. Beads were vortexed and incubated at 
room temperature for 10 minutes. Following incubation, 48 µL beads were mixed with 32 µL 
H2O and this mixture was added to the 50 µL library and incubated for 10 minutes. Following 
incubation, the mixture was placed on the magnet stand for 5 minutes. The supernatant (130 µL) 
was saved and added to a clean microcentrifuge tube in which 15 µL beads was mixed in and 
incubated for 10 minutes. Following incubation, the mixture was placed on the magnet stand for 
5 minutes. The supernatant was removed and the beads were given an 80% ethanol wash twice. 
Following the second wash, the ethanol was completely removed from the tube and the beads 
were left to dry for 15 minutes. The tubes were taken off the magnet stand and 30 µL of H2O was 
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mixed with the beads by pipetting and the mixture was incubated at room temperature for 10 
minutes. Following incubation, the mixture was placed on the magnet stand for 5 minutes. 25 µL 
of the supernatant was removed and added to clean microcentrifuge tubes and this was the 
purified DNA library.    
3.10 - DNA Sequencing  
Following DNA library preparation and purification, samples were sent for bioanalysis. 
Ideally, to succeed to the sequencing step, bioanalyzer results for each sample must show sharp 
peaks at 35 base pairs and 10380 base pairs and a curved peak at about 400-500 base pairs. 
Following bioanalysis, samples were re-purified to eliminate any unwanted adapter dimers and 
qPCR was performed on all samples. Illumina Next-Generation Sequencing was performed.  
3.11 - Analysis 
 Microbiome Analysis  
MetaPhlAn (metagenomic phylogenetic analysis) was performed from our 
sequencing results to profile the composition of the microbial community from each 
DNA library.  
 Statistical Analysis 
A Wilcoxon signed-rank test was performed at the genus and species levels given 
the data provided by the MetaPhlAn output. The control group was compared to the 
treated group at different time points. A Wilcoxon test is used to determine if any given 
genus was differentially abundant between time points. In addition, a Kruskal-Wallis test 
was performed to determine significant alterations in the microbiome when comparing 
the control group and treated group prior to dosing and during dosing. This test revealed 
an LDA (linear discriminant analysis) score was provided for genera that were 
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significantly altered which describes ranked discriminative features consistent across the 
study.   
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Chapter 4 - Results  
 
4.1 - DNA Isolation Nanodrop Results (Spectrophotometric Analysis) 
 4.1a - DNA concentration  
DNA was isolated from fecal samples using the protocol mentioned in the 
materials and methods. Following isolation, DNA concentrations were determined using 
the Nanodrop machine and concentrations for each sample are listed in the charts below. 
Concentrations varied as some samples had concentrations <100 while others had 
concentrations >100 and a few had concentrations >50 ng/ul. All samples listed had 
reasonable concentrations for proceeding to the library preparation and sequencing step. 
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Figure 13. DNA concentrations of isolated DNA from fecal samples 
4.1b - Ratios (DNA Quality)  
While DNA concentration was obtained following DNA isolation, so was the 
A260/A280 and A260/A230 ratios. These ratios are indicative of DNA sample quality 
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and contamination. It was imperative that the A260/A230 ratio fell within the 1.7 to 2.1 
range otherwise the DNA needed to be isolated again. An A260/A230 ratio that did not 
fall in this range was indicative of DNA contamination, which did occur during some 
DNA isolations. From abnormal results of the A260/A230 ratios, it became apparent that 
the wash buffer from the DNA isolation kit was unusable and a new wash buffer needed 
to be implemented in order to maintain quality DNA. Following this wash buffer 
exchange, samples were isolated and ratios returned to normal. The poor quality DNA 
isolated using the subpar wash buffer was not recorded and do not appear in the figures 
below as this DNA was discarded.   
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Subject Collection Date A260/A280 A260/A230 
1496 
8/6/2018 1.79 1.91 
10/8/2018 1.81 1.96 
11/18/2018 1.84 1.83 
11/26/2018 1.85 2.01 
12/2/2018 1.85 1.8 
12/7/2018 1.83 1.74 
1497 
10/8/2018 1.83 1.91 
10/12/2018 1.84 1.84 
11/18/2018 1.86 1.83 
11/26/2018 1.82 1.78 
12/2/2018 1.86 1.8 
12/7/2018 1.83 1.86 
1500 
10/8/2018 1.85 1.88 
10/26/2018 1.84 1.79 
11/18/2018 1.85 1.87 
11/26/2018 1.83 1.86 
12/2/2018 1.81 1.82 
12/7/2018 1.85 1.55 
1501 
8/6/2018 1.79 2.03 
10/8/2018 1.83 1.68 
11/18/2018 1.86 1.79 
11/26/2018 1.82 1.91 
12/2/2018 1.84 1.8 
12/7/2018 1.84 1.94 
1532 
8/6/2018 1.78 1.91 
11/5/2018 1.76 1.62 
11/13/2018 1.81 1.88 
11/19/2018 1.81 1.76 
11/26/2018 1.79 1.87 
12/1/2018 1.84 1.63 
1533 
8/6/2018 1.8 1.78 
11/5/2018 1.83 2.11 
11/13/2018 1.85 2.03 
11/19/2018 1.84 1.91 
11/26/2018 1.85 1.87 
12/1/2018 1.87 1.74 
1542 
8/6/2018 1.77 1.66 
11/5/2018 1.79 1.78 
11/13/2018 1.84 1.98 
11/19/2018 1.85 1.97 
11/26/2018 1.83 2.01 
11/30/2018 1.93 1.93 
1543 
8/6/2018 1.78 1.82 
11/5/2018 1.82 2.05 
11/13/2018 1.87 2.09 
11/19/2018 1.84 1.84 
11/26/2018 1.83 1.65 
12/1/2018 1.83 1.98 
1544 
8/6/2018 1.78 2.02 
11/5/2018 1.82 2.12 
11/13/2018 1.85 2.13 
11/19/2018 1.83 1.95 
11/26/2018 1.85 2.02 
12/1/2018 1.83 2.08 
 






4.2 - Gel electrophoresis (DNA quality)  
Following DNA isolation and Nanodrop analysis, DNA samples were run on an agarose 
gel to depict DNA quality. Stool samples typically have a less defined band on gels. We looked 
for a bright band located closer to the well as a marker for high quality samples. Most samples 
did maintain this result, however, a few samples resulted in bright bands toward the end of the 
gel. While this indicates more degraded DNA, it was still determined that these samples were of 
high enough quality to be used for sequencing. It should be noted that due to technological 
difficulties, we were unable to provide photographic evidence of some gels. Therefore, these gels 
were run again (lanes 1 and 2 for each subject) at a much later date, in order to provide 
photographic evidence for the thesis. It is possible that some DNA that appears more degraded 
than others had been stored in the freezer longer or thawed a greater number of times. 












Figure 15. Gel electrophoresis of isolated DNA from fecal samples 
4.3 - qPCR Analysis Using Primers for Gut Microbiota 
Our first approach to examine changes in gut microbiota was via qPCR using bacterial 
primers that we predicted would be abundant or result in altered abundance upon opioid 
administration. It is important to first note that we performed qPCR using nine primers, but only 
included results from eight of the primers as the Bifidobacteria primer maintained low CT values 














addition, the Spirochaetes primer was relatively unreliable as it resulted in low CT values in 
control wells on some plates.  
CT values indicate abundance of whichever primer was used in the DNA sample. Values 
≥ 40 are considered undetermined, meaning that the bacteria of the primer is essentially non-
existent in the sample. Values between 30-40 indicate moderate abundance levels and values ≤29 
indicate highly abundant bacteria, with decreasing values indicating increasing abundance. 
CT values for both primers bacterial universal 1 and bacterial universal 2 remained in a 
range from 9-12 for all subjects at all dates, meaning there was consistently very abundant 
bacteria levels in the samples. Figure 16a depicts the CT values at chronological dates of each of 
the eight primers for each of the control samples. According to these results, there is much 
variability at the different dates, however, overall it can be see that pathogenic bacteria such as 
Escherichia coli and Clostridium remained close to undetermined CT values (depicted as nearing 
forty on the graphs), meaning these bacteria were not abundant in the subjects throughout the 
study. On the other hand, bacteria such as Lactobacillus and Spirochaetes maintained much 
lower CT values, in the range of 15-25, meaning these bacteria were much more abundant in the 
subjects throughout the study. Bacteroides maintained CT values in the range of 25-28, meaning 
it was abundant in the subjects as well. Lastly, Fusobacteria resulted in CT values ranging 
somewhere between the non-existent bacteria, E. coli and Clostridium, and the abundant 
bacteria, Bacteroides, meaning it was relatively, but not very, abundant in the subjects 




Figure 16a. qPCR results showing CT values for 8 primers of control subjects at each time point in the study. Y-axis values represent CT 
values.  
Figure 16b depicts the CT values at each date for the treated group. Similar relative 
abundances are found in these subjects as found in the control subjects. However, it is important 
to look at the changes in the CT values for the bacterial primers during dosing compared to 
before dosing. For example, in subjects 1497 and 1532 there is an increase in the CT values for 
Fusobacteria during dosing and post-dosing, meaning there was a decrease in Fusobacteria 
abundance, possible as a result of the opioid dosing. However, in subjects 1500, 1543, and 1544 
the same trend cannot be seen, in which Fusobacteria maintains fairly constant CT values, 
indicating that the change in abundance in subjects 1497 and 1532 may have been spontaneous 
and not as a result of opioid dosing. Subject 1532 has a unique profile in which the CT values for 
Fusobacteria, Spirochaetes, and Bacteroides increased at the second week of dosing, indicating a 
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Figure 16b. qPCR results showing CT values from 8 primers for Buprenorphine-treated subjects at each time point in the study. Y-axis 
values represent CT values.  
Figures 19 (a-i) illustrate a more in depth look at the change in CT values for a specific 
bacterial primer in each subject at the different time points. Error bars were added to each bar in 




Control subject 1496, shown in Figure 17a had variability especially in bacteria Lactobacillus, 
Fusobacteria, and Spirochaetes. However, Bacteroides, Clostridium, and E. coli remained mostly 
constant across all time points. Figure 17b illustrates the CT values for control subject 1501. This 
subject had less variability than subject 1496, but it was still apparent especially in Lactobacillus. 
However, the levels of the remaining primers were consistent with those found in subject 1496. 
CT values for control subject 1533 are shown in figure 17c. There is variability in the CT values 
in this subject as well, but the levels of each bacteria remain consistent with the previous control 
subjects. Spirochaetes resulted in greater variability, similar to the variability seen in subject 
1496. These results could be inaccurate given the sometimes-dysfunctional primer. CT values for 
Clostridium also showed variation as the pre-dosing values are lower than the dosing and post-
dosing values. However, the standard deviations for the pre-dosing results are large enough that 
one of the wells could have skewed the results because of contamination. Figure 17d depicts the 
CT values for control subject 1542. Like the other controls, the bacterial abundances varied at 
each date, but remained consistent with the overall abundance of each bacteria.  Subject 1497, 
shown in Figure 17e was dosed with buprenorphine. The abundances remained constant 
according to the CT values from all the primers, excluding Fusobacteria for which the CT values 
increased during dosing from around 27 to 37. This means Fusobacteria likely became much less 
abundant after opioid dosing. Figure 17f depicts CT values for bacterial primers in 
Buprenorphine treated subject 1500. CT values for primers Clostridium and Fusobacteria 
remained constant from pre-dosing to two weeks dosing. For primers Bacteroides, Spirochaetes, 
and E. coli CT values decreased from pre-dosing to two weeks dosing while CT values for 
Lactobacillus increased. However, variability in the post-dosing CT values makes it difficult to 
assert whether or not these changes were a result of treatment. Aside from this, relative 
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abundances of each primer were similar according to CT values as compared to the other 
subjects. Subject 1532 shown in Figure 17g was also administered Buprenorphine. CT values 
were not conclusive of any change as a result of dosing because of variability in the pre-dosing 
results. Although, results for Fusobacteria showed a greatly increased CT value after two weeks 
of dosing, indicating decreased abundance in the subject. Ignoring variability in pre-dosing 
results, it does appear that Lactobacillus abundance increased during dosing and Spirochaetes 
abundance decreased during dosing, as indicated by their CT values. Figure 17h depicts the CT 
values for bacteria in subject 1543. Values remained fairly constant across all time periods, 
indicating no significant change in these bacteria’s abundances as a result of dosing. However, 
there does appear to be a slight increase in CT values of Bacteroides at two weeks dosing, 
meaning a possible decrease in Bacteroides abundance. Lactobacillus CT vales also appear to 
vary during dosing; however, the first pre-dosing CT value is too close to those of during dosing 
to be able to make a valid inference about the effect of dosing on the abundance of Lactobacillus. 
Spirochaetes CT values vary greatly across the time points, again indicating a possible 
dysfunction in the Spirochaetes primer. Figure 17i depicts CT values for Buprenorphine treated 
subject 1544. CT values for Spirochaetes and Bacteroides increased during dosing as compared 
to pre-dosing or post-dosing meaning their abundances likely decreased during dosing. While 
there was some variation, CT values for Clostridium, E. coli, Fusobacteria, and Lactobacillus 
remained constant at all time points. Additionally, abundances as explained by the CT values 
were similar to those found in the other subjects.  
It is difficult to definitively state whether the qPCR results match the sequencing results. 
There were some consistencies in that Escherichia coli and Clostridium proved to be nearly 
nonexistent in most subjects according to qPCR results and sequencing results. However, 
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phylum Fusobacteria and genus Bacteroides were at least moderately abundant in most subjects 
according to qPCR results but was at 0% relative abundance for most subjects according to 
sequencing results. Lactobacillus and Spirochaetes were abundant in most subjects according to 
qPCR results and their abundances varied depending on the collection date, but it is difficult to 
determine if this variation is consistent with the sequencing results’ variation.  
 




Figure 17b. CT Values from 6 primers for control subject 1501 at each time point in the study  
 




Figure 17d. CT values from 6 primers for control subject 1542 at each time point in the study  
 




Figure 17f. CT values from 6 primers for Buprenorphine-treated subject 1500 at each time point in the study  
 




Figure 17h. CT values from 6 primers for Buprenorphine-treated subject 1543 at each time point in the study 
 
Figure 17i. CT values from 6 primers for Buprenorphine-treated subject 1544 at each time point in the study  
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4.4 - Library Preparation 
 4.4a - Nanodrop Results  
  DNA concentration  
DNA concentrations following library preparation were significantly 
lower than that of the original isolated DNA samples. Most samples fell within a 
range of 3-12 ng/µL. Concentrations below 3 were not ideal, however, their 
bioanalyzer results offered the most insight into whether or not the sample could 
be used for sequencing. If the concentration was low but had normal bioanalyzer 
results, the sample was accepted for sequencing. There were a handful of samples 
with poor bioanalyzer results indicating low concentrations that were not accepted 
for sequencing and had to be prepped again. Following this, only one sample 
(1501 collection date 12/2) maintained the low concentration and poor 
bioanalyzer result, but was sent for sequencing regardless due to time constraints. 
Concentrations were found via the nanodrop machine, but Vladimir Lee, who 
performed the bioanalysis, also determined concentrations of the libraries as a 
verification.  
  Ratios  
Ratios provided by the nanodrop machine were less accurate following 
library preparation because of the significantly lower concentrations of the 
samples. At low concentrations, the A260/A230 ratio can be much higher or 
lower than expected because the nanodrop machine cannot perform adequately 
when samples are at concentrations below 10ng/µL.  
4.4b - Bioanalyzer results  
The bioanalyzer determined whether the prepared DNA libraries were of good 
quality before continuing to the sequencing step. The bioanalyzer provides the average 
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size and concentration of DNA fragments. The sizes of our libraries were between 400-
500 bp and the concentrations were between 1-15 nM, with higher concentrations being 
more desirable. Ultimately, the bioanalyzer produces a large linear range that indicates 
any impurities in the DNA purifications. The two sharp peaks are size markers, one low 
and one high, which are used to align the ladder. The high marker is also used to quantify 
the size of the middle, more broad peak, which represents the DNA fragments in the 
library. Any small peaks between the first sharp peak and the middle broad peak indicates 
unwanted adapter dimers which implied the need for further purification. Samples 
resulting in a lower middle peak generally corresponded to libraries of very low 
concentration and those libraries with nearly flat peaks were successfully reproduced to 
result in higher concentration and better sequencing results down the line. Our 









































































































































Figure 18. Bioanalyzer results for each DNA library from each sample at each collection date 
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4.5 - Sequencing Results  
MetaPhlAn output provided relative abundances of bacteria from the level of kingdom 
down to the level of species. Because we performed shotgun sequencing rather than just 16s, the 
MetaPhlAn output showed bacterial abundance as well as relative abundances of other kingdoms 
such as Archaea, Eukarya, and Viruses. Bacteria were vastly more abundant than each of the 
other three kingdoms. Viruses and Eukarya were found only in one subject at one time point and 
although Archaea was found at varying levels in different subjects at different time points, it was 
still significantly less abundant than bacteria. Focusing on bacterial abundances, we were able to 
create figures based on phylum and genus level to depict alterations in the microbiota. For a 
more in-depth understanding of the abundances shown in each heat map, one can refer to 
supplemental figures 1, 2a, 2b, and 2c as they contain the numerical value for each of the relative 
abundances.  
Figure 19 illustrates the relative abundances of the bacteria found in the stool sample 
DNA, which is representative of the gut microbiota at the phylum level, at the pre-dosing time 
point. Our sequencing results only include data for the pre-dosing time point from the date most 
closely associated with the beginning of the dosing period. In general, Firmicutes is the most 
dominant phylum, followed by subdominant phyla Euryarchaeota, Spirochaetes, Actinobacteria, 
Bacteroidetes, and Proteobacteria are the subdominant phylum. Each subject varies greatly with 
the relative abundances among the subdominant phyla. Subject 1496 is unique in that 
Euryarchaeota is not apparent. Subjects 1500, 1542, and 1543 are unique in that Spirochaetes is 





Figure 19. Phylum level gut microbiome composition in each subject pre-dosing. Each column indicates an individual sample in 
chronological order: 1496 (lane 1), 1497 (lane 2), 1500 (lane 3), 1501 (lane 4), 1532 (lane 5), 1533 (lane 6), 1542 (lane 7), 1543 (lane 8), 1544 
(lane 9).  
Figure 20 depicts the relative abundances of bacteria in the gut of all subjects during pre-
dosing at the genus level. As shown, there is a lot of variation in the gut microbial composition 
across subjects. However, on average the most abundant bacteria is Lactobacillus, followed by 
Eubacterium, Methanobrevibacter (under the Kingdom Archaea), Subdoligranulum, 
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Phasolarctobacterium, Treponema, Ruminococcus, Methanosphaera (Kingdom Archaea), 
Coprococcus, and Helicobacter. Thirty-six other genus came back with some relative abundance 
(>3) and eleven genera had a relative abundance of zero across all subjects.  In sample 1496, the 
most abundant bacteria include Eubacteria (20%) and Coprococcus (16.6%), both falling under 
the phylum Firmicutes and the class Clostridia. Treponema was also 13% abundant and the 
remaining genus were less than 10% abundant. More specifically, Subdolingranulum, Blautia, 
and Prevotella ranged between 7.5 and 5% abundant, respectively. Lactobacillus and 
Ruminococcus were only about 4% abundant. In sample 1497, Methanobrevibacter and 
Subdolingranulum are almost equally abundant, at 20.3% and 20.1% abundance, respectively. 
Methanosphaera and Lactobacillus are also almost equally abundant at 16% and 15.7% 
abundance. Phascolarctobacterium was 12.7% abundant, Treponema was 7.8% abundant, and 
Helicobacter was 3.3% abundant. The remaining genus were <1% abundant. In subject 1500, 
Lactobacillus made up almost half of the genome at 44%. Methanobrevibacter was 14.6% 
abundant and Subdoligranulum was 11.8% abundant. Phascolarctobacterium was 8.4%, 
methanosphaera was 5.8%, Helicobacter was 5.2%, Peptostreptococcaceae was 3%, and Blautia 
was 1.4% abundant. The remaining genus were <1% abundant. In subject 1501, Eubacterium 
made up more than half of the genome at 56.3% abundance. Streptococcus was the next most 
abundant bacteria at only 8.3% and Mathnaosphaera fell close behind at 7.4%. Treponema, 
Subdolingranulum, Methanobrevicater, Dorea, Blautia, Collinsella, Peptostreptococcae, 
Phascolarctobacterium, and Helicobacter were between 1-5% abundant, listed in order of their 
relative abundances. All remaining genus were <1% abundant. In subject 1532, Lactobacillus  is 
the most dominant genus at 36.8%, similar to subject 1500. Additionally, Methanobrevibacter is 
the next most abundant, like in subject 1500, at 12%. However, following these genera are 
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Phascolarctobacterium at 8.4%, Eubacteriumat 7.3% and Subdoligranulum at 5.1%. 
Faecalibacterium, Dorea, Coprococcus, Erysipelotrichaecea, and Catenibacterium were all 
around 4% abundant. Following these were Blautia, Clostridium, and Prevotella at 2.8%, 2%, 
and 1.2%, respectively. The remaining genera were <1% abundant. Like subjects 1500 and 1532, 
the microbiome of subject 1533 is dominated by Lactobacillus at 39.5%. However, this subject is 
unique in that Ruminococcus is nearly as abundant at 31.2%. Methanobrevibacter falls behind 
these genera at 10.4% and Treponema was 6.2% abundant. Subdoligranulum and 
Phascolarctobacterium were about 3% abundant and the remaining genera were <1% abundant. 
Subject 1542 is unique in that it essentially does not have a dominant genus. Lactobacillus and 
Helicobacter are the most abundant at only 10.8% each. Nine other genera including 
Eubacterium, Subdoligranulu, Faecalibacterium, Methanosphaera, Erysipelotrichaceae, 
Methanobrevibacter, Blautia, Ruminococcus, and Coprococcus are between 5-9% abundant, 
listed in order of decreasing abundances, making up almost 70% of the microbiome. Subject 
1543 is similar to 1542 in that the most abundant species are not relatively that abundant with 
Phascolarctobacterium at 21.4% and Subdoligranulum at 21.2%. Methanobrevibacter  was 
13.5%, Ruminococcus was 10.6%, Eubacterium was 7.3%, Faecalibacterium was 5.8%, and 
Enterococcus was 4.1% abundant. Enterococcus, Coprococcus, Prevotella, Erysipelotrichaeceae 
and Lachnospiraceae were all about 2% abundant. Subject 1544 similarly had lower abundance 
of dominant bacteria with Treponema at 19.5%. Phascolarctobacterium, Eubacterium, and 
Methnaobrevibacter were all about 10% abundant, followed by Subdoligranulum, Enterococcus, 
Dorea, and Lactobacillus ranging from 5-8% abundance. Coprococcus, Prevotella, and 
Peptostreptococcaceae were around 2-3% abundant. According to the relative abundances given 
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by MetaPhlAn, the variety in the pre-dosing microbiomes is apparent and makes analysis of 
microbiome alterations difficult as result of opioid dosing. 
 
Figure 20. Genus level gut microbiome composition in each subject pre-dosing. Each column indicates an individual sample in 
chronological order: 1496 (lane 1), 1497 (lane 2), 1500 (lane 3), 1501 (lane 4), 1532 (lane 5), 1533 (lane 6), 1542 (lane 7), 1543 (lane 8), 1544 
(lane 9). 
In figure 21, the change in bacterial abundance at the genus level is characterized in each 
subject from pre-dosing to one week of dosing. Genera are clustered together using Euclidian 
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distances to indicate bacteria that acted similarly during the study. This figure indicates which 
genera increased, decreased, or remained the same after 1 week of dosing. Genera that remained 
at a relative abundance of zero were excluded from the figure.  
Eubacterium decreased in abundance in control subjects 1496 and 1542, increased in 
abundance in control subject 1501, and remained constant in control subject 1533. Meanwhile its 
abundance remained constant in treated subjects 1497 and 1500, decreased in treated subjects 
1532 and 1543, and increased in treated subject 1544. The remaining genera resulted in similar 
unpredictable variations in abundance at the two time points, regardless of the subject being in 
the control or treated group. We chose to focus more heavily on the pre-dosing to two-week 





Figure 21. Genus level gut microbial composition pre-dosing and at one week of dosing for each subject. Control subjects are shown on the 
left: 1496 (lane 1), 1500 (lane 2), 1533 (lane 3), 1542 (lane 4) while Buprenorphine-treated subjects are shown on the right: 1497 (lane 5), 1501 
(lane 6), 1532 (lane 7), 1543 (lane 8), 1544 (lane 9).  
Figure 22 depicts the change in bacterial abundance at the genus level from pre-dosing to 
two weeks of dosing in each subject. Again, genera were clustered using Euclidian distances. 
Control groups are shown on the left of the figure while Buprenorphine treated groups are shown 
on the right.  
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In control subject 1496, the three most dominant genera before dosing were Eubacterium 
at 20.3%, Coprococcus at 16.6%, and Treponema at 13.8%. At the two week “dosing” time 
point, the three most dominant genera were Treponema at 21.7%, Coprococcus at 20.6%, and 
Prevotella at 12.3%. Eubacterium fell from 20.4% to 3.3% abundance and Prevotella increased 
from 5.3% to 12.3% abundance after two weeks of dosing. Additionally, there was almost a 
tenfold increase in genus Desulfovibrio from .028% to .297% and more than a seven fold change 
in the genus Brachyspira from .001% to .009%. While these are very low relative abundances 
compared to the other genera, the size of fold change is significant when addressing the 
variability in the microbiome, especially considering this being a control subject. In control 
subject 1501, the three most dominant genera before dosing were Eubacterium at 56.3%, 
Streptococcus at 8.3%, and Methanosphaera at 7.4%. At the two week “dosing” time point, the 
three most dominant genera were Eubacterium at 60.4%, Treponema at 8% and 
Methanobrevibacter at 7.1%. Streptococcus decreased from 8.3% to 0.08%, Methanosphaera 
decreased from 7.4% to 3.2%, Treponema increased from 5.1% to 8%, and Methanobrevibacter 
increased from 3% to 7.1% at the two week “dosing” time point. In control subject 1533, the 
dominant genera prior to dosing were Lactobacillus at 39.4%, Ruminococcus at 31.2%, and 
Methanobrevibacter at 10.4%. At the two week “dosing” time point, the dominant genera were 
Lactobacillus at 42.3%, Ruminococcus at 28.2%, and Treponema at 9.8%. Methanobrevibacter 
decreased from 10.4% to 8% and Treponema increased from 6.2% to 9.8%. This subject 
maintained reasonably consistent abundances at these two time periods. In control subject 1542, 
the dominant genera before dosing were Lactobacillus at 10.8%, Helicobacter at 10.8%, and 
Eubacterium at 8.7%. At the two week dosing mark, the dominant genera were 
Methanobrevibacter at 43.5%, Subdoligranulum at 17.2% and Lactobacillus at 9.2%. 
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Methanobrevibacter increased from 6.6% to 43.5%, Subdoligranulum increased from 8.7% to 
17.2%, Helicobacter decreased from 10.8% to .12%, and Eubacterium decreased from 8.7% to 
.9%.  This subject resulted in highly varied abundances despite it being a control subject. 
However, it is interesting to note that while other abundances varied, Lactobacillus remained 
fairly constant. 
In Buprenorphine treated subject 1497, the three dominant genera before dosing were 
Methanobrevibacter at 20.3%, Subdoligranulum at 20.1%, and Methanosphaera at 16%. After 
two weeks of dosing, the three most dominant genera were Lactobacillus at 67.8%, 
Methanobrevibacter at 10.5%, and Subdoligranulum at 6.4%. Lactobacillus increased from 
15.7% to 67.8%, a more than threefold increase, while Methanosphaera dropped from 16% to 
4.2% after two weeks of dosing. Treponema also dropped from 7.8% to 2.4% and 
Phascolarctobacterium dropped from 12.7% to 5.3% after two weeks of dosing. Additionally, 
there was nearly a threefold increase in Peptostreptococcaceae from .015% to .056%. In 
Buprenorphine treated subject 1500, the three most dominant genera before dosing were 
Lactobacillus at 44%, Methanobrevibacter at 14.6%, and Subdoligranulum at 11.8%. After two 
weeks of dosing, the most dominant genera were Lactobacillus at 22.6%, Methanobrevibacter at 
22.6%, and Phascolarctobacterium at 17.3%. Subdoligranulum decreased from 11.8% to 6.8% 
and Phascolarctobacterium increased from 8.4% to 17.3% after two weeks of dosing.  The 
dominant genera in subject 1532 before dosing were Lactobacillus at 36.8%, 
Methanobrevibacter at 12.1%, and Phascolarctobacterium at 8.4%. After two weeks of dosing, 
the dominant genera were Lactobacillus at 91.6%, Methanobrevibacter at 1.8%, and 
Catenibacterium at 1%. Phascolarctobacterium decreased from 8.4% to .04% and although 
Catenibacterium became one of the three dominant genera after dosing, it actually decreased 
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from 3.6% to 1%. This subject resulted in a large increase in Lactobacillus while all other genera 
were depleted at the two-week dosing mark. In subject 1542, the dominant genera before dosing 
were Phascolarctobacterium at 21.4%, Subdoligranulum at 21.2%, and Methanobreibacter at 
13.5%. After two weeks of dosing, the dominant genera were Subdoligranulum at 21.5%, 
Phascolarctobacterium at 16.8%, and Prevotella at 9.4%. Methanobrevibacter decreased from 
13.5% to 6.1% and Prevotella increased from 2.6% to 9.4%. It should be noted that the results 
indicated 0 Lactobacillus before or after dosing. In subject 1544, the dominant genera before 
dosing were Treponema at 19.5%, Phascolarctobacterium at 10.7%, and Eubacterium at 10.6%. 
After two weeks of dosing, the dominant genera were Lactobacillus at 30.9%, Eubacterium at 
13.8%, and Phascolarctobacterium at 13.2%. Treponema decreased from 19.5% to .36% and 
Lactobacillus increased from 4.7% to 30.9% after two weeks of dosing. Additionally, 





Figure 22. Genus level gut microbial composition pre-dosing and at two weeks of dosing for each subject. Control subjects are shown on the 
left: 1496 (lane 1), 1500 (lane 2), 1533 (lane 3), 1542 (lane 4) while Buprenorphine-treated subjects are shown on the right: 1497 (lane 5), 1501 
(lane 6), 1532 (lane 7), 1543 (lane 8), 1544 (lane 9). 
Figure 23 depicts the change in bacterial abundance at the genus level in each substance 
from pre-dosing to two weeks of dosing to one week post dosing.  
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In control subject 1496, at the pre-dosing mark the three most dominant genera were 
Eubacterium, Coprococcus, and Treponema. At the during dosing mark and the post dosing 
mark, the most dominant genera were Treponema, Coprococcus, and Prevotella. This data 
indicates some consistency in the mirobiome given the similarity in the microbiome at two of the 
three time points. In control subject 1501, the three most dominant genera at the pre-dosing mark 
were Eubacterium, Streptococcus, and Methanosphaera. At the two week dosing mark, the most 
dominant genera were Eubacterium, Treponema, and Methanobrevibacter. At the one week post 
dosing mark, the most dominant genera were Lactobacillus, Methanobrevibacter, and 
Subdoligranulum. There is some consistency from pre-dosing to during dosing, but there is great 
variation at the post-dosing mark. In control subject 1533, the dominant genera at the pre-dosing 
mark were Lactobacillus, Ruminococcus, and Methanobrevibacter. At the two week dosing mark 
the most dominant genera were Lactobacillus, Ruminococcus, and Treponema. At the post-
dosing mark the most dominant genera were Ruminococcus, Lactobacillus, and Treponema. 
Subject 1533 shows the most consistency in the microbiome across subjects, implying that great 
variation does not always exist. However, while the dominant genera remained fairly consistent, 
the relative abundances of such genera did vary. While the relative abundances of 
Methanobrevibacter and Treponema remained constant over all the time points, Lactobacillus 
and Ruminococcus abundances varied. Lactobacillus decreased greatly after one week post 
dosing as compared to pre-dosing or during dosing time points. Additionally, Ruminococcus 
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relative abundance increased after one week post dosing as compared to pre-dosing or during 
dosing time points. In control subject 1542, the most dominant genera at the pre-dosing mark 
were Lactobacillus, Helicobacter, and Eubacterium. At the during dosing mark, the most 
dominant genera were Methanobrevibacter, Subdoligranulum, and Lactobacillus. At the post-
dosing mark the most dominant genera were Phascolarctobacterium, Subdoligranulum, and 
Prevotella. Again, variation in the microbiome is shown in this sample as the dominant genera 
change at the different time points.  
In Buprenorphine treated subject 1497, the dominant genera prior to dosing were 
Methanobrevibacter, Subdoligranulum, and Methansosphaera. After two weeks of dosing, the 
dominant genera were Lactobacillus, Methanobrevibacter, and Subdoligranulum. After one 
week post dosing, the dominant genera were Methanobrevibacter, Subdoligranulum, and 
Phascolarctobacterium. It is interesting to note that prior to dosing Lactobacillus was 15.7% 
abundant, at two weeks of dosing it was 67.8% abundant, and after one week post dosing it was 
8.7% abundant. Methanobrevibacter was 20.3% abundant before dosing, reduced to 10.5% 
abundant after twoo weeks of dosing, and returned to 22.2% abundant one week after dosing. 
Subdoligranulum followed a similar pattern to the abundances of Methanobrevibacter at the 
different time points. Buprenorphine administration resulted in a marked decreased in Archaea, 
an increase in the bacteria Lactobacillus and a decrease in the bacter Subdoligranulum. In 
Bupreonorphine treated subject 1500, the dominant genera pre-dosing were Lactobacillus, 
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Methanobrevibacter, and Subdoligranulum. After two weeks of dosing, the dominant genera 
were Lactobacillus, although reduced by almost half its original relative abundance, 
Methanobrevibacter, and Phascolarctobacter. After one week post-dosing, the dominant genera 
were Eubacteria, Treponema, and Methanobrevibacter. Lactobacillus was reduced from nearly 
44% abundance before dosing, to 23% during dosing, to only 2% at one week post dosing. 
Eubacterium remained nearly the same level of abundance pre-dosing and after two weeks of 
dosing at just .3% and .4%, but vastly increased after one week post dosing, making up over half 
of the genome at 56% relative abundance. In Buprenorphine treated subject 1532, the most 
dominant genera prior to dosing were Lactobacillus, Methanobrevibacter, and 
Phascolarctobacterium. After two weeks of dosing, the dominant genera were Lactobacillus, 
Methanobrevibacter, and Catenibacterium. After one week post dosing, the dominant genera 
were Lactobacillus, Faecalibacterium, and Prevotella. Lactobacillus increased from 37% 
abundance to nearly 92% abundance during dosing and after one week post dosing, it returned to 
about 36% relative abundance. The relative abundance of Methanobrevibacter decreased during 
dosing and returned to similar abundance after one week post dosing. Similarly, 
Subdoligranulum decreased during dosing and returend to similar relative abundance at one 
week post dosing. In Buprenorphine treated subject 1543, the dominant genera prior to dosing 
were Phascolarctobacterium, Subdoligranulum, and Methanobrevibacter. After two weeks of 
dosing, the dominant genear were Subdoligranulum, Phascolarctobacterium, and Prevotella and 
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after one week post dosing the dominant genera were Subdoligranulum, Phascolarctobacterium, 
and Methanobrevibacter. The relative abundance of Methanobrevibacter decreased during 
dosing and returned to original abundance after one week post dosing. Subdoligranulum actually 
remained at a fairly consistent relative abundance across all time points. Phascolarctobacterium  
had decreased relative abundance during dosing compared to pre-dosing, but maintained the 
lower abundance after one week post dosing. In Buprenorphine treated subject 1544, the pre-
dosing dominant genera were Treponema, Phascolarctobacterium, and Eubacterium. After two 
weeks of dosing, the dominant genera were Lactobacillus, Eubacterium, and 
Phascolarctobacterium and after one week post dosing the dominant genera were 
Phascolarctobacterium, Eubacterium, and Methanobrevibacter. The relative abundance of 
Treponema greatly decreased during dosing from almost 20% to .4% and there was a slight 
increase after one week post dosing to become 6% abundant. Lactobacillus greatly increased 
from pre-dosing to during dosing starting at just 5% abundance to 31% abundance and returned 
to 8% abundance after one week post dosing. Phascolarctobacterium and Eubacterium gradually 
increased across the time points. The relative abundance of Methanobrevibacter decreased from 
pre-dosing to during dosing and returned to a relative abundance higher than the original after 




Figure 23. Genus level gut microbial composition at the pre-dosing, two-weeks of dosing, and one-week post dosing time points for each 
subject. Control subjects are shown on the left: 1496 (lane 1), 1500 (lane 2), 1533 (lane 3), 1542 (lane 4) while Buprenorphine-treated subjects 
are shown on the right: 1497 (lane 5), 1501 (lane 6), 1532 (lane 7), 1543 (lane 8), 1544 (lane 9). 
Figure 24 depicts the change in bacterial abundance at the phylum level in each subject 
from pre-dosing to two weeks of dosing to one-week post dosing. As shown by the heat map, 
while there appear to be changes in the relative abundances in the control group subjects, 
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changes in the abundances are more apparent in the treatment group subjects, indicated by the 
more noticeable changes in color.  
In control subject 1496, the three most dominant phylum were Firmicutes, Spirochaetes, 
and Bacteroidetes before dosing and at both the two-week dosing mark and one week post 
dosing mark. The relative abundances of each remained fairly consistent, especially between the 
two week dosing and one week post dosing marks. In control subject 1501, the two most 
dominant phylum were Firmicutes and Euryarchaeota at the pre dosing, two-week dosing, and 
one-week post dosing marks. The pre-dosing and two-week during dosing samples had 
extremely similar relative abundances of all phyla. The one-week post dosing sample showed 
some variation especially in the relative abundances of Euryarchaeota, Bacteroidetes, and 
Spirochaetes. In control subject 1533, the three most dominant genera were Firmicutes, 
Euryarchaeota, and Spirochaetes at the pre-dosing, two-week dosing, and one-week post dosing 
marks. However, while the pre-dosing sample followed this exact order of abundance, both the 
two-week dosing and one-week post dosing samples had slightly higher relative abundances of 
Spriochaetes compared to Euryarchaeota. Overall, the relative abundances of each phyla 
remained fairly similar at each time point, except Bacteroides which was slightly increased in the 
one-week post dosing sample. In control subject 1542, the dominant phyla were more varied than 
in the other control subjects. At the pre-dosing mark, the dominant phyla were Firmicutes, 
Euryarchaetoa, and Proteobacteria, listed in order of relative abundances. At the two-week 
dosing mark, the dominant genera were Euryarchaeota and Firmicutes. At the one-week post 
dosing mark, the dominant phyla were Firmicutes, Bacteroidetes, and Euryarchaeota. The 
relative abundances of Firmicutes and Euryarchaeota were most similar at the pre-dosing mark 
and one-week post dosing mark, but were altered in the two-week dosing sample. Overall, we 
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saw much more consistency in the control group subjects individually at each time point at the 
phylum level than at the genus level.  
In Buprenorphine treated subject 1497, the dominant phyla were Firmicutes and 
Euryarchaeota at the pre-dosing, two-week dosing, and one-week post dosing time points. 
However, Firmicutes significantly increased during dosing from 52% to 81% and returned to 
50% one week post dosing. Euryarchaetoa decreased during dosing from 36% to 15% and 
returned to 35% one week post dosing. Phylum Spirochaetes decreased during dosing from 8% 
to 2% and returned to 7% one week post dosing. In Buprenorphine treated subject 1500, the 
dominant phylum pre-dosing and at two weeks of dosing were Firmicutes, Euryarchaeota, and 
Proteobacteria. The relative abundance of Firmicutes decreased from 72% to 60%, that of 
Euryarchaetoa increased from 20% to 33%, and that of Proteobacteria remained fairly constant at 
6% and 5%. At one-week post dosing, the dominant phyla were Firmicutes, Spirochaetes, and 
Euryarchaeota. Firmicutes returned to 70% relative abundance. Spirochaetes increased from 
almost non-existent levels to 17% abundance and Euryarchaeota decreased to 6% relative 
abundance. In Buprenorphine treated subject 1532, the dominant phylum was Firmicutes, 
making up between 83% to 98% of the genome at the different time points. Before dosing, the 
relative abundance of Firmicutes was 85% which increased to 98% at two weeks dosing and 
decreased to 83% after one week post dosing. The relative abundance of Euryarchaeota started at 
12%, decreased to 2% during dosing and increased to 7% after one week post dosing. 
Bacteroidetes interestingly was nearly nonexistent before dosing and during dosing at just 1.2% 
and .4%, but its relative abundance increased to almost 8% after one week post dosing. In 
Buprenorphine treated subject 1543, the dominant phylum at all time periods was again 
Firmicutes and it remained at a relative abundance between 76% and 83% throughout. 
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Euryarchaeota was more abundant than Bacteroidetes prior to dosing, but became less abundant 
than Bacteroidetes at two weeks of dosing and after one week post dosing, Euryarchaeota 
returned to being more abundant. In Buprenorphine subject 1544, the dominant phylum was 
again Firmicutes. However, prior to dosing, the relative abundance was 64.5% and increased to 
86% at two weeks of dosing and began to decrease to 74% at one-week post dosing. 
Spirochaetes was 19.5% relatively abundant prior to dosing, but was almost completely depleted 
at two weeks of dosing at just .4%. At one week post dosing its relative abundance began 




Figure 24. Phylum level gut microbial composition at the pre-dosing, two weeks of dosing, and one week post dosing time points for each 
subject. Control subjects are shown on the left: 1496 (lane 1), 1500 (lane 2), 1533 (lane 3), 1542 (lane 4) while Buprenorphine-treated subjects 
are shown on the right: 1497 (lane 5), 1501 (lane 6), 1532 (lane 7), 1543 (lane 8), 1544 (lane 9). 
 4.5a - Statistical Analysis 
Statistical analysis was performed at both the genus level and species level in the 
control group versus the Buprenorphine treated group. We ran a non-parametric Wilcoxin 
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signed-rank test at both genus and species levels which provided p values to determine 
whether there was a significant differential abundance between time points, either pre-
dosing to two weeks dosing or two weeks dosing to one week post-dosing, in treated 
subjects. According to the results, there was no significance alteration in the gut 
microbiome. While individually, subjects’ microbiomes did obviously change, the 
Wilcoxin test suggested that there was no significant difference in abundance for all 
genus/species included in the study when comparing pre-dosing to two week dosing 
samples as well as two week dosing to one week post dosing. While there were p-values 
that did indicate significance for certain genera (a p-value <.05), these genera resulted in 
a zero for relative abundance at at least one time point, as shown in the third column of 
Figure 25. Unfortunately, the presence of a zero in the data for these genera causes the p-




Figure 25. P values indicating significance or insignificance between the pre-dosing time point and the two-week 








Figure 26. P values indicating significance or insignificance between the two-week dosing time point and the one-week 







We also ran a Kruskal Wallis test at the genus level and the genera that resulted in 
significant LDA scores can be seen figure 27.  The Kruskal Wallis test was set up using 
LefSe software with Saline vs. Treated as the class and time points as the subclass. The 
genera that are present on the graph are the only genera that resulted in differential 
abundance. The red bars in the graph indicate genera that are most closely associated 
with the saline group while the green bar indicates the genus that is most closely 
associated with the treatment group.  
 
Figure 27. Kruskal Wallis test results for significant alterations in genera abundance in the gut microbiome in the control group versus the 
treatment group.  
Some difficulty in running statistical analysis was a result of our smaller sample size. P 
values were calculated but many were unreliable given the amount of zeros for a specific genus 
across samples. While there are probability models that can be used to combat sparsity in data 




Chapter 5 - Discussion  
 
The purpose of our study was to provide evidence for the hypothesis that the gut 
microbiome alters in response to repeated opioid administration. Opioids cause a wide range of 
side effects including gut motility problems, inflammation, cognitive and behavioral changes, 
among others. In recent studies, the gut microbiome has been linked to a growing amount of 
physiological problems for humans, including many of the same side effects caused by opioids. 
Our study was comprised of nine animals, divided into a control group and treatment group. The 
treatment group was administered the partial agonist opioid drug, Buprenorphine, daily for a two 
week time span. Fecal samples were collected from each subject over the course of the study. 
DNA was isolated and analyzed for quality and DNA libraries were prepared and purified. 
Shotgun sequencing was performed to provide an in-depth look into the composition of the gut 
microbial community of each subject.  
From this, we discovered that the gut microbiome is highly variable among individuals. 
This variation proves it difficult to identify trends in alterations in the microbiome among groups 
of individuals. The hope was that despite individual variation, each microbiome would maintain 
similar dominant genera, making it possible to identify alterations in dominant genera as a result 
of opioid administration. However, variation among individuals proved to be so vast that it 
became nearly impossible to find significant alterations in the microbiome as a result of opioid 
administration. While our subjects were fed the same diet and kept in the same environment, it’s 
possible that variation was a result of gender, age, or other biological differences.  
It was expected that Bacteroidetes, Firmicutes, and Proteobacteria would be the dominant 
bacterial phylum in the microbiome before dosing (Chen). As indicated by Figure 19, Firmicutes 
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is by far the most dominant phylum found in each subject. Bacteroidetes and Proteobacteria are 
apparent in each subject; however, they are much less abundant relative to Firmicutes. In seven 
of the nine subjects (1497, 1500, 1501, 1532, 1533, 1543, 1544), Euryarchaeota is significantly 
more abundant than Bacteroidetes or Proteobacteria, however, Euryarchaeota is a phylum falling 
under the kingdom Archaea rather than Bacteria.  
We did not expect to find such high levels of Archaea in the fecal samples, as many 
papers discussing the gut microbiome focused heavily on bacterial species, with little or no 
mention of Archaea. However, it is known that Euryarchaeota are typically found in the gut. 
More specifically, Methanobrevibacter and Methanosphaera reside in the gut with the former 
usually being more abundant. Both of these Euryarchaeota are considered methanogens and there 
are two mechanisms by which methanogens might affect health. The first mechanism is their 
designation as a hydrogenotrophic group, meaning it plays a role in hydrogen transfer and thus a 
role in anaerobic fermentation of organic matter. This implies that methanogens encourage the 
growth of fermenting bacteria which can be either pathogenic or commensal bacteria. The 
second mechanism is their ability to transform heavy metals or metalloids into volatile 
methylated derivatives, which are toxic. It has been theorized that methanogens play a potential 
role in GI disorders but there have been conflicting results, leading to an inability to confirm this 
hypothesis (Horz). Based on this information, we would expect that methanogen abundance 
would increase as a result of repeated Buprenorphine administration because of the predicted 
increase in pathogenic bacteria as well as gut related issues, such as constipation and 
inflammation, as a result of opioid administration. However, in most, but not all, of the treated 
subjects, the relative abundance of Methanobrevibacter decreased after two weeks of dosing and 
in some of the control subjects, Methanobrevibacter relative abundance actually increased. 
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Therefore, there is no clear correlation between opioid administration and methanogen 
abundance.  
Ignoring Euryarchaeota, there was only one subject, 1500, in which Firmicutes, 
Proteobacteria, and Bacteroidetes were the three most dominant phylum. Again, ignoring 
Euryarchaetoa, several subjects including, 1496, 1497, 1501, 1533, and 1544, had a genome 
comprised mostly of Firmicutes, unexpectedly followed by Spirochaetes rather than 
Proteobacteria or Bacteroidetes. Additionally, Actinobacteria was more abundant in several 
subjects than either one of or both Proteobacteria and Bacteroidetes.  
It was expected that genera such as Clostridium, Enterococcus, Lactobacillus and 
Ruminococcus would be found in the microbiome under the phylum Firmicutes as well as 
Bacteroides and Prevotella under the phylum Bacteroidetes with Bacteroides, Prevotella, and 
Ruminococcus being the most abundant overall. In addition, Prevotella was expected to be the 
most dominant under the phylum Bacteroidetes (Power). 
Sequencing results showed a wide variety of genera under Firmicutes depending on the 
subject. As expected, Lactobacillus was highly or moderately abundant in most subjects and 
Ruminococcus was at least somewhat abundant in all subjects and highly or moderately abundant 
in some. However, contrary to expectations, there were not genera that were equally highly 
abundant in all subjects. Additionally, Clostridium and Enterococcus were minimally abundant 
in some subjects, but nonexistent in most. Eubacterium was found in several subjects and was 
highly abundant relatively in some.  
It was expected that Prevotella would be more abundant than Bacteroides because of the 
difference between the Rhesus monkey genome and human genome. Prevotella was the most 
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abundant genus under Bacteroidetes according to our results. However, the CT values from the 
Bacteroides primer ranged between 20-30 which did indicate at least moderate abundance within 
the subjects, yet the sequencing results did not result in any Bacteroides abundance. 
It was expected that opioid administration would alter the microbiome to increase 
pathogenic bacteria such as Staphylococci, Clostridia (Ruminococcus, Butyrovibrio, 
Fusobacterium, Eubacterium, and Peptostreptococcus), and Veillonellae and decrease beneficial 
bacteria such as Lactobacilli and Bifidobacteria. Interestingly, Bifidobacteria was nonexistent in 
any subject at any time, going against previous understanding that such bacteria plays a very 
important role in the gut barrier (Rastall). This could be a result of the difference between the 
human microbiome and rhesus monkey microbiome. Lactobacillus abundance did change during 
dosing, but in many subjects its abundance actually increased. It is possible that this change in 
Lactobacillus could have an effect on GABA regulation, leading to changes in the brain affecting 
mood and behavior, despite its classification as a beneficial bacterium. Potentially pathogenic 
bacteria, especially under the class Clostridia were abundant in subjects. However, Staphylococci 
and Veillonellae were nonexistent even after dosing, another possible result of the difference 
between human and rhesus monkey microbiomes.  It was determined that alterations in the 
microbiome were found to be insignificant based on a Wilcoxin signed-rank test.  
Some possible limitations in the study leading to the insignificant results could be the 
DNA quality, sample size (both or either the number of subjects or the amount of sample 
collections), the use of a weaker analgesic as opposed to Morphine or the like, and the duration 
of the dosing period. DNA from fecal samples as illustrated by electrophoretic analysis appears 
more degraded than normal. While this is expected for fecal samples, it is possible that our DNA 
quality was lower than anticipated because DNA isolation and library preparation were not 
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performed immediately after the other, allowing time for DNA to further degrade before use. 
Additionally, it is possible that significant alterations in the gut microbiome occur only after an 
extended period of opioid administration, greater than two weeks. Furthermore, statistical 
analysis may have been more powerful had the sample size been larger. 
The qPCR performed in this study was limited as far as validating sequencing results. 
First, it would have been beneficial to sequence the DNA samples prior to choosing qPCR 
primers so as to include more representative bacterial primers. However, this would not have 
been possible given the circumstances of the project including time restraints and resources. In 
addition, it was more efficient to choose primers that had already been designed and included in 
previous publications. Designing our own primers would have been difficult because of the 
amount of primers we wanted to use. Because we relied on pre-designed primers we could not be 
sure of the effectiveness prior to purchasing and buying said primers, leading to circumstances 
like that of the Spirochaetes primer in which results may be invalid and the Bifidobacterium 
primers whose results we could not include because of its ineffectiveness throughout the study.  
Ultimately, the gut microbiome variation among and within individuals is so great that 
we could not successfully provide evidence for our hypothesis. In the future, it would be ideal to 
create an experimental design that studied gut microbiota alterations in parallel to mood/behavior 
alterations, inflammatory response, and any other host responses. Additionally, this would be 
more reliable given a longer dosing period, as depressed mood has been correlated to opioid 
administration following greater than thirty days, and a larger sample size. However, this 
experimental design is very difficult to execute given limitations in subject and resource 
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Supplemental Figure 1. Relative abundances of subjects at each time point (excluding the second pre-dosing day) at the phylum level. 
Firmicutes Euryarchaeota Spirochaetes Proteobacteria Actinobacteria Bacteroidetes Fusobacteria Synergistetes Eukaryota_nonameViruses_noname
1496 pre 74.57135 0 13.78755 3.58272 2.78711 5.27126 0 0 0 0
1496 1 wk dosing 38.16266 0 29.52673 9.3872 3.04818 19.87523 0 0 0 0
1496 2 wk dosing 59.57853 0 21.68886 2.15435 4.26458 12.31368 0 0 0 0
1496 2 days post 46.28882 0 34.24135 5.31021 3.19243 10.96719 0 0 0 0
1496 1 wk post 54.1699 0 21.91332 5.62442 3.20595 15.0864 0 0 0 0
1497 pre 67.48564 21.85133 7.18459 2.66205 0.62774 0.18865 0 0 0 0
1497 1 wk dosing 57.01044 31.28334 6.43999 4.07086 0.9201 0.27525 0 0 0 0
1497 2 wk dosing 80.72991 14.64148 2.36144 1.97497 0.17619 0.11601 0 0 0 0
1497 2 days post 74.94096 13.94803 7.43521 3.03052 0.48248 0.16281 0 0 0 0
1497 1 wk post 49.5089 34.50094 6.67662 8.52999 0.45721 0.32633 0 0 0 0
1500 pre 72.30366 20.41079 0.00771 6.16569 0.39181 0.72034 0 0 0 0
1500 1 wk dosing 63.22424 30.80377 0.00852 4.88111 0.25635 0.82601 0 0 0 0
1500 2 wk dosing 59.29088 32.88794 0 5.43123 0.89508 1.49488 0 0 0 0
1500 2 days post 63.8916 26.03789 0.00143 7.43759 0.92367 1.70782 0 0 0 0
1500 1 wk post 70.20105 5.74318 17.42389 4.1488 1.11416 1.36893 0 0 0 0
1501 pre 80.72365 10.4738 5.06122 1.20005 2.03546 0.50582 0 0 0 0
1501 1 wk dosing 70.54785 7.1755 14.55558 4.31508 1.65545 1.75054 0 0 0 0
1501 2 wk dosing 78.5849 10.32136 8.02215 1.13768 0.60964 1.32428 0 0 0 0
1501 2 days post 78.10198 2.77277 15.20629 1.38783 1.4824 1.04873 0 0 0 0
1501 1 wk post 77.84066 19.16797 0 1.31621 0.34978 1.32538 0 0 0 0
1532 pre 85.43492 12.06356 0.9256 0.09463 0.33099 1.1503 0 0 0 0
1532 1 wk dosing 71.10043 20.38211 2.55724 1.07499 0.29158 4.59365 0 0 0 0
1532 2 wk dosing 97.62603 1.79521 0.09367 0.02033 0.0736 0.39116 0 0 0 0
1532 2 days post 85.94126 9.31245 0.53717 0.32637 0.64942 3.23333 0 0 0 0
1532 1 wk post 83.26123 6.85268 0.73406 0.42713 0.95406 7.75193 0 0 0.01891 0
1533 pre 81.97856 10.40369 6.19463 0.69464 0.12001 0.60849 0 0 0 0
1533 1 wk dosing 77.16996 12.9586 8.30667 0.9544 0.1422 0.46817 0 0 0 0
1533 2 wk dosing 79.9828 8.10853 9.84633 0.78676 0.19284 1.08274 0 0 0 0
1533 1 wk post 82.42932 7.34905 8.58952 0.22156 0.24793 1.16262 0 0 0 0
1533 2 wk post 72.80473 8.67865 11.84835 0.12672 0.49386 6.0477 0 0 0 0
1542 pre 68.67822 13.39742 0.13136 10.80376 3.19314 3.74205 0.05406 0 0 0
1542 1 wk dosing 50.5287 40.97924 1.39723 1.01179 1.07126 5.01178 0 0 0 0
1542 2 wk dosing 43.21889 50.80545 2.87753 0.6601 1.24099 0.9876 0 0 0 0.2094
1542 2 days post 51.41388 45.15033 1.00609 0.29048 0.77003 1.3692 0 0 0 0
1542 1 wk post 70.71572 12.44264 0 0.3051 0.7086 15.82795 0 0 0 0
1543 pre 82.65318 13.49408 0.09203 0.47528 0.69666 2.58877 0 0 0 0
1543 1 wk dosing 79.33105 4.98811 0 0.48955 1.43237 13.72249 0 0.03643 0 0
1543 2 wk dosing 81.78543 6.06215 0 0.18121 2.45669 9.51452 0 0 0 0
1543 2 days post 64.56556 30.15412 0.27666 0.18526 0.94035 3.87804 0 0 0 0
1543 1 wk post 75.67617 12.76928 0 0.06345 0.63635 10.85475 0 0 0 0
1544 pre 64.47221 10.08301 19.50734 1.85995 0.89723 3.18026 0 0 0 0
1544 1 wk dosing 85.24226 4.56479 0.3732 1.21491 1.7995 6.80534 0 0 0 0
1544 2 wk dosing 85.74842 4.82189 0.36217 4.15865 0.89044 4.01844 0 0 0 0
1544 2 days post 78.73653 4.44503 0.70722 1.32365 0.98065 13.80692 0 0 0 0
















































Lactobacillus 3.96 0.57 4.21 0.34 7.84 15.72 21.65 67.81 52.56 8.74 43.97 34.27 22.56 29.36 2.07
Methanobrevibacter 0.00 0.00 0.00 0.00 0.00 20.25 21.16 10.46 10.87 22.16 14.58 21.52 22.55 21.72 4.24
Eubacterium 20.35 3.48 3.32 6.09 2.03 0.22 0.10 0.02 0.02 0.04 0.31 0.18 0.42 2.14 55.80
Subdoligranulum 7.44 3.63 8.30 6.26 6.44 20.09 16.60 6.37 12.88 19.71 11.79 14.45 6.85 10.97 2.48
Phascolarctobacterium 0.85 1.14 1.72 1.44 1.24 12.65 14.59 5.31 6.63 16.88 8.41 6.86 17.29 14.72 1.29
Treponema 13.79 29.46 21.68 21.89 34.22 7.76 6.44 2.36 7.44 6.67 0.00 0.00 0.00 0.00 17.42
Ruminococcus 3.83 2.47 3.57 6.66 1.80 0.57 1.65 0.39 1.44 1.48 0.25 0.31 0.75 1.55 4.06
Prevotella 5.27 19.82 12.28 15.07 10.93 0.28 0.28 0.12 0.16 0.33 0.72 0.83 1.49 1.22 1.37
Methanosphaera 0.00 0.00 0.00 0.00 0.00 15.97 10.13 4.18 3.08 12.32 5.83 9.28 10.34 4.32 1.50
Coprococcus 16.60 7.87 20.61 17.75 9.95 0.28 0.16 0.08 0.15 0.44 0.69 0.34 0.46 0.21 0.57
Helicobacter 3.51 9.15 1.86 5.06 4.40 3.25 4.07 1.97 3.03 8.53 5.22 3.54 2.94 4.72 4.13
Faecalibacterium 2.25 3.38 4.24 3.08 1.72 0.04 0.10 0.04 0.02 0.01 0.38 0.35 0.45 0.31 0.23
Blautia 6.49 2.34 3.95 4.07 3.35 0.48 0.32 0.20 0.24 0.36 1.38 2.10 1.81 1.22 0.84
Dorea 2.43 3.17 1.03 1.27 2.97 0.74 0.63 0.24 0.36 0.72 0.87 1.58 3.19 0.85 1.30
Catenibacterium 0.00 3.59 1.85 3.01 1.47 0.00 0.16 0.04 0.14 0.11 0.09 0.00 0.07 0.00 0.54
Erysipelotrichaceae 0.79 1.42 1.15 1.18 1.40 0.04 0.04 0.01 0.01 0.04 0.10 0.00 0.01 0.00 0.20
Collinsella 2.64 2.89 3.99 3.02 2.92 0.96 0.91 0.17 0.47 0.46 0.38 0.24 0.89 0.88 0.94
Peptostreptococcaceae 4.59 2.10 2.57 1.70 4.38 0.01 0.04 0.06 0.00 0.06 2.96 1.43 3.83 0.76 0.58
Clostridiales 0.62 1.56 1.41 0.27 0.65 0.00 0.09 0.00 0.00 0.00 0.03 0.00 0.08 0.06 0.09
Roseburia 0.65 0.88 0.89 0.57 0.58 0.28 0.42 0.09 0.23 0.56 1.00 1.30 1.43 1.60 0.09
Enterococcus 0.02 0.02 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Streptococcus 3.44 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Bilophila 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.93 1.35 2.49 2.72 0.00
Megasphaera 0.14 0.25 0.53 0.24 0.17 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Mitsuokella 0.00 0.03 0.02 0.04 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Clostridium 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Lachnospiraceae 0.10 0.18 0.15 0.12 0.16 0.29 0.39 0.04 0.20 0.30 0.06 0.03 0.05 0.05 0.01
Desulfovibrio 0.03 0.23 0.30 0.55 0.87 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.02
Veillonella 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Parabacteroides 0.00 0.06 0.03 0.01 0.03 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Actinomyces 0.13 0.12 0.23 0.16 0.26 0.00 0.01 0.00 0.01 0.00 0.01 0.02 0.01 0.05 0.10
Oscillibacter 0.02 0.02 0.03 0.03 0.03 0.06 0.08 0.03 0.02 0.05 0.02 0.03 0.04 0.08 0.03
Acinetobacter 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Olsenella 0.02 0.04 0.04 0.03 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Sutterellaceae 0.00 0.01 0.00 0.01 0.01 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00
Bacteroides 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.48 0.00
Butyrivibrio 0.00 0.00 0.00 0.00 0.00 0.05 0.00 0.02 0.03 0.00 0.00 0.00 0.00 0.00 0.00
Acidaminococcus 0.02 0.06 0.04 0.03 0.09 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Clostridiales_Family_XIII_Incertae_Sedis0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Actinobacillus 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Brachyspira 0.00 0.06 0.01 0.02 0.02 0.00 0.00 0.00 0.00 0.01 0.01 0.01 0.00 0.00 0.00
Viruses 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Burkholderia 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Propionibacterium 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.02
Rothia 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Aerococcus 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.03
Fusobacterium 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Corynebacterium 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.04
Citrobacter 0.04 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Pyramidobacter 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Neisseria 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterobacter 0.00 0.00 0.00 0.01 0.02 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Entamoeba 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Methanocaldococcaceae 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.02 0.00 0.00 0.00 0.00 0.00
Anaerostipes 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00
Gemella 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00















































Lactobacillus 0.00 3.40 0.00 0.00 58.21 36.84 28.09 91.63 47.63 35.54 39.41 14.40 42.33 26.98 16.10
Methanobrevibacter 3.04 4.45 7.13 2.47 14.75 12.06 20.38 1.80 9.31 6.85 10.40 12.96 8.10 7.35 8.68
Eubacterium 56.34 48.30 60.37 62.88 0.02 7.26 1.45 0.74 3.06 3.95 0.51 0.39 0.45 1.15 1.02
Subdoligranulum 3.41 2.50 3.17 1.48 5.70 5.10 20.13 0.91 5.78 5.40 3.39 3.63 2.60 2.16 3.29
Phascolarctobacterium 1.71 1.86 3.25 2.31 5.15 8.39 2.11 0.04 0.13 2.15 3.25 4.85 2.21 2.58 2.13
Treponema 5.06 14.56 8.02 15.21 0.00 0.93 2.56 0.09 0.54 0.72 6.19 8.31 9.85 8.59 11.85
Ruminococcus 0.64 2.43 6.93 9.10 0.39 0.52 0.35 0.04 2.36 0.23 31.24 50.86 28.15 44.77 43.60
Prevotella 0.48 1.75 1.31 1.05 1.33 1.15 4.59 0.39 3.19 7.64 0.61 0.47 1.08 1.16 6.05
Methanosphaera 7.43 2.72 3.20 0.30 4.42 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Coprococcus 1.00 1.47 0.54 0.42 0.64 4.37 2.52 0.56 3.95 4.61 0.29 0.27 0.44 0.34 0.19
Helicobacter 1.20 4.32 1.13 1.38 0.55 0.09 0.98 0.02 0.19 0.31 0.69 0.95 0.79 0.22 0.13
Faecalibacterium 0.09 0.18 0.27 0.08 0.34 4.81 4.34 0.45 7.63 7.95 0.12 0.25 0.23 0.31 0.32
Blautia 2.48 1.33 0.77 0.64 1.91 2.80 2.43 0.82 3.55 3.10 0.79 0.57 0.66 0.73 1.76
Dorea 2.77 3.71 1.53 0.63 2.11 4.58 2.36 0.57 1.43 3.52 1.01 0.69 1.06 0.88 0.94
Catenibacterium 0.97 1.02 0.82 0.26 0.10 3.65 4.70 0.99 4.74 4.48 1.00 0.87 1.18 1.37 2.23
Erysipelotrichaceae 0.12 0.13 0.06 0.00 0.00 4.35 1.96 0.82 3.00 4.86 0.12 0.05 0.11 0.15 0.11
Collinsella 1.98 1.52 0.53 1.36 0.35 0.32 0.25 0.06 0.59 0.87 0.12 0.13 0.18 0.23 0.49
Peptostreptococcaceae 1.75 0.47 0.64 0.19 2.46 0.37 0.32 0.02 0.71 1.84 0.29 0.03 0.06 0.14 0.00
Clostridiales 0.00 0.02 0.00 0.02 0.00 0.05 0.00 0.01 0.16 2.19 0.20 0.04 0.33 0.63 0.20
Roseburia 0.18 0.12 0.07 0.06 0.70 0.34 0.19 0.00 0.16 0.46 0.33 0.20 0.16 0.20 0.92
Enterococcus 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Streptococcus 8.28 3.56 0.08 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Bilophila 0.00 0.00 0.00 0.00 0.76 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Megasphaera 0.94 0.00 0.03 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Mitsuokella 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Clostridium 0.00 0.00 0.00 0.00 0.00 1.96 0.00 0.00 1.45 2.74 0.00 0.00 0.00 0.00 0.00
Lachnospiraceae 0.00 0.01 0.01 0.00 0.03 0.00 0.00 0.02 0.02 0.07 0.00 0.00 0.00 0.01 0.00
Desulfovibrio 0.00 0.00 0.01 0.00 0.00 0.00 0.10 0.00 0.13 0.11 0.00 0.00 0.00 0.00 0.00
Veillonella 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.10 0.09 0.00 0.00 0.00 0.00 0.00
Parabacteroides 0.02 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.05 0.11 0.00 0.00 0.00 0.00 0.00
Actinomyces 0.05 0.11 0.06 0.09 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.01 0.00 0.00
Oscillibacter 0.03 0.03 0.06 0.03 0.00 0.05 0.13 0.00 0.09 0.08 0.02 0.02 0.02 0.03 0.00
Acinetobacter 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00
Olsenella 0.00 0.01 0.01 0.01 0.00 0.01 0.04 0.01 0.05 0.06 0.00 0.00 0.00 0.01 0.00
Sutterellaceae 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00
Bacteroides 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Butyrivibrio 0.00 0.00 0.00 0.00 0.09 0.00 0.00 0.00 0.00 0.00 0.00 0.04 0.00 0.00 0.00
Acidaminococcus 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.03 0.00 0.00 0.00 0.00 0.00
Clostridiales_Family_XIII_Incertae_Sedis0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Actinobacillus 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Brachyspira 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.02 0.00 0.00 0.00 0.00 0.00
Viruses 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Burkholderia 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Propionibacterium 0.00 0.01 0.01 0.01 0.00 0.00 0.00 0.00 0.01 0.03 0.00 0.00 0.00 0.00 0.00
Rothia 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Aerococcus 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.03 0.00 0.00 0.00 0.00
Fusobacterium 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Corynebacterium 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Citrobacter 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Pyramidobacter 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Neisseria 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterobacter 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Entamoeba 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.02 0.00 0.00 0.00 0.00 0.00
Methanocaldococcaceae 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Anaerostipes 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Gemella 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00















































Lactobacillus 10.81 3.04 9.17 12.73 0.00 0.00 0.00 0.00 1.27 0.00 4.66 9.12 30.85 31.68 8.21
Methanobrevibacter 6.59 25.89 43.47 41.15 12.44 13.49 4.99 6.06 30.15 12.77 10.08 4.56 4.82 4.45 14.32
Eubacterium 8.72 2.58 0.93 0.97 6.40 7.30 5.40 6.19 2.66 6.34 10.56 18.27 13.82 13.35 15.31
Subdoligranulum 8.68 19.11 17.20 21.61 19.29 21.24 17.68 21.53 28.37 24.28 8.29 6.46 3.71 3.73 6.95
Phascolarctobacterium 0.81 10.40 2.33 0.97 19.53 21.35 24.05 16.81 20.90 17.79 10.66 20.76 13.23 8.82 20.10
Treponema 0.10 1.37 2.88 1.01 0.00 0.09 0.00 0.00 0.28 0.00 19.51 0.37 0.36 0.71 6.06
Ruminococcus 5.19 1.37 1.15 0.31 4.06 10.59 9.17 8.55 3.28 4.88 0.31 4.21 1.45 0.82 3.00
Prevotella 3.74 4.98 0.99 1.37 15.59 2.56 13.53 9.35 3.22 10.62 2.99 6.77 4.00 13.78 4.70
Methanosphaera 6.81 15.09 7.34 4.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Coprococcus 4.66 2.53 3.28 4.46 2.10 2.95 1.88 1.86 0.87 1.94 3.11 2.33 3.17 1.69 3.65
Helicobacter 10.80 1.01 0.12 0.17 0.19 0.48 0.44 0.15 0.19 0.00 0.96 0.78 3.90 1.03 0.47
Faecalibacterium 7.26 0.89 0.24 0.51 7.15 5.83 6.86 6.15 1.30 6.27 1.68 3.41 3.60 5.52 3.61
Blautia 6.23 3.96 0.73 2.40 2.19 1.31 3.46 4.69 2.13 1.95 2.08 5.32 3.06 1.74 4.59
Dorea 3.21 1.21 3.24 0.80 1.49 2.22 0.91 1.38 0.57 2.04 5.54 2.88 4.13 4.22 1.70
Catenibacterium 1.10 1.38 1.40 0.28 1.70 1.31 3.08 8.54 0.29 2.10 3.41 1.81 1.21 1.26 1.33
Erysipelotrichaceae 6.65 2.30 2.11 5.50 2.86 2.31 1.48 1.49 2.11 3.64 2.25 0.73 1.90 1.71 2.51
Collinsella 2.92 1.01 1.20 0.69 0.69 0.66 1.41 2.40 0.84 0.64 0.90 1.76 0.88 0.95 0.18
Peptostreptococcaceae 0.00 0.11 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 2.09 2.06 1.36 0.45 0.71
Clostridiales 1.98 0.35 0.74 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.71 6.07 3.25 2.57 0.26
Roseburia 0.74 0.06 0.24 0.47 0.58 0.11 0.99 0.52 0.09 0.44 0.44 1.29 0.42 0.66 1.02
Enterococcus 0.10 0.00 0.00 0.00 1.79 4.07 1.58 1.47 0.19 2.36 7.39 0.00 0.05 0.17 0.00
Streptococcus 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Bilophila 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Megasphaera 1.41 0.96 0.39 0.00 0.53 1.38 0.21 0.00 0.00 0.00 0.00 0.29 0.29 0.00 0.00
Mitsuokella 0.14 0.00 0.00 0.00 1.01 0.66 1.85 2.22 0.01 1.65 0.00 0.00 0.00 0.12 0.00
Clostridium 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Lachnospiraceae 0.11 0.13 0.00 0.29 0.00 0.00 0.33 0.04 0.36 0.00 0.00 0.07 0.02 0.12 0.70
Desulfovibrio 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.30 0.20 0.12 0.31
Veillonella 0.81 0.00 0.06 0.11 0.03 0.00 0.39 0.31 0.03 0.01 0.21 0.15 0.22 0.13 0.01
Parabacteroides 0.00 0.03 0.00 0.00 0.24 0.03 0.20 0.16 0.66 0.24 0.19 0.03 0.02 0.03 0.27
Actinomyces 0.05 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Oscillibacter 0.00 0.01 0.00 0.00 0.00 0.01 0.02 0.00 0.01 0.00 0.01 0.02 0.01 0.00 0.00
Acinetobacter 0.00 0.00 0.54 0.12 0.00 0.00 0.00 0.00 0.00 0.00 0.43 0.00 0.00 0.00 0.00
Olsenella 0.16 0.07 0.04 0.08 0.02 0.03 0.02 0.05 0.10 0.00 0.00 0.04 0.01 0.03 0.02
Sutterellaceae 0.00 0.00 0.00 0.00 0.11 0.00 0.05 0.00 0.00 0.06 0.31 0.13 0.00 0.00 0.00
Bacteroides 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Butyrivibrio 0.00 0.14 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Acidaminococcus 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Clostridiales_Family_XIII_Incertae_Sedis0.05 0.00 0.00 0.00 0.00 0.00 0.00 0.02 0.11 0.00 0.05 0.00 0.00 0.00 0.00
Actinobacillus 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.05 0.18 0.00
Brachyspira 0.03 0.02 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Viruses 0.00 0.00 0.21 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Burkholderia 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.16 0.00 0.00 0.00 0.00
Propionibacterium 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Rothia 0.07 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Aerococcus 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fusobacterium 0.05 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Corynebacterium 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Citrobacter 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Pyramidobacter 0.00 0.00 0.00 0.00 0.00 0.00 0.04 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Neisseria 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.04 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterobacter 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Entamoeba 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Methanocaldococcaceae 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Anaerostipes 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Gemella 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
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